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ABSTRACT 
 
 
Traumatic spinal cord injury is a devastating neurologic condition in both veterinary and 
human medicine and despite research yielding numerous potential interventions with remarkable 
efficacy demonstrated in rodent models, none has advanced to successful clinical translation. Pet 
dogs’ predilection for sustaining spinal cord injury, typically due to intervertebral disc herniation 
or vertebral column fracture, makes them a suitable clinical model in which putative 
interventions for spinal cord injury can be tested. In recent years, there has been a growing body 
of experimental evidence that attests to the efficacy of chondroitinase ABC in promoting axonal 
regeneration and functional recovery after spinal cord injury by reactivating neuroplasticity. 
Chondroitinase ABC is a commercialized bacterial enzyme that selectively deglycosylates 
chondroitin sulfate proteoglycans and thereby disrupts the perineuronal nets that limits axonal 
regeneration. In this 60-dog clinical trial, we examined the therapeutic effect of chondroitinase 
ABC on the primary outcome measure, pelvic-thoracic limb gait coordination, and several 
secondary parameters, including motor- and sensory-evoked potentials and urinary bladder 
compliance. While our study failed to detect a therapeutic effect in chronic, severe 
thoracolumbar spinal-injured dogs, it has established drug safety in a clinical large animal model. 
Thus, this study has provided a platform for future investigations in which the dose, route and 
timing of chondroitinase ABC administration, as well as patient selection, can be adjusted to 
maximize its potential therapeutic effect and benefit spinal-injured human and veterinary 
patients, especially if a more treatment-responsive subgroup could be identified. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
 
Pathophysiology of Spinal Cord Injury 
 
Spinal cord injury in human and veterinary medicine  
Traumatic spinal cord injury is a devastating neurologic condition in human medicine 
that has a current global prevalence of 236 – 1,009 cases per million1. In the United States, it 
affects ~ 253,000 people with an annual incidence of 11,000; typical causes include violence 
such as bullet wounds, traffic accidents, and sport- and occupation-related injuries2,3. The 
associated annual socioeconomic costs are estimated to exceed $4 billion in the United States 
and $1.6 billion in the United Kingdom4 (www.spinal-research.org). In addition to long-term 
disabilities caused by motor and sensory impairment, concomitant neurologic dysfunctions, such 
as urinary incontinence, autonomic dysreflexia and respiratory dysfunction, can drastically 
impact on quality of life and life expectancy of the affected individuals2,5,6.  
For these compelling reasons, spinal cord injury has attracted intensive research efforts 
over the past three decades and a large number of interventions of various modalities, including 
biological, pharmacological and physical, have been developed (Figure 1.1). However, despite 
research yielding numerous potential interventions with remarkable efficacy demonstrated in 
experimental rodent models, none has advanced to successful clinical translation.  
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Figure 1.1 Examples of Treatment Modalities for Spinal Cord Injury2,7. 
 
A desirable translational model would have more comparable spinal cord size, anatomy, 
physiology and pathophysiology to humans; pet dogs are suitable because of their predilection 
for sustaining spinal cord injury, typically due to intervertebral disc herniation or vertebral 
column fracture in T3 – L3 segments, that can lead to severe motor and sensory impairment in 
the pelvic limbs, and ‘upper motor neuron’ lower urinary tract dysfunction8.   
A subset of spinal-injured pet dogs suffer from injuries of the most severe grade that will 
result in chronic paraplegia and inability to initiate voluntary urination, which is equivalent to 
ASIA Grade Aa in humans8 – 10. These comparable features thus render pet dogs a suitable pre-
human clinical model for spinal cord injury research and successful clinical translation of 
potential therapies will benefit human and veterinary patients alike.  
 
                                                
a ASIA Grade A: in accordance with the classification scheme proposed by the American Spinal 
Injury Association 
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Anatomic damage in spinal cord injury 
In humans and dogs, the spinal cord begins as a continuation of the medulla oblongata as 
it exits the foramen magnum and terminates at the level of ~ L1 and ~ L5 – L6 vertebra, 
respectively2,11,12. The spinal cord of both species consists of cervical, thoracic, lumbar, sacral 
and coccygeal segments; the human spinal cord comprises 31 segments that are topographically 
defined by the 31 paired spinal nerves: 8 cervical, 12 thoracic, 5 lumbar, 5 sacral and 1 
coccygeal2, while the dog spinal cord is composed of ~ 36 segments: 8 cervical, 13 thoracic, 7 
lumbar, 3 sacral and ~ 5 coccygeal11,12.  
Within the spinal cord, the centrally located gray matter consists of neurons, neuroglia 
and nerve bundles entering or exiting the spinal cord at the dorsal or ventral horns; the white 
matter comprises highly organized, longitudinally arranged axonal bundles that communicate 
sensory and motor information in ascending and descending tracts between centers in the brain 
and their somatic and visceral effectors in the periphery2,11,12 (Figure 1.2). 
 
Figure 1.2 Spinal Cord Gray Matter. Afferents enter at the dorsal horn and either (1) directly 
synpase with efferent neurons (red cricle) to form a reflex arc (e.g. patellar reflex), or (2) first 
synapse with the interneurons, which in turn synpase with the efferent neurons (yellow circle) 
that innervate effector organs, or communiate with centers within the brain (green pathway). 
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The ascending white matter tracts carry sensory input to the brain and they usually start 
with the prefix ‘spino-’ and end with the name of the target site within the brain; the descending 
tracts carry motor inpulses from the brain to their effector organs and these tracts usually begin 
with the prefix that indicate the brain region giving rise to the fibers and end with the suffix ‘-
spinal’2 ,12 (Figure 1.3).  
(a) 
(b) 
Figure 1.3 Comparison of Human (a) and Dog (b) White Matter Tracts.  
Ascending or sensory tracts in red; decending or motor tracts in green2,11,12. 
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Because of its structural and functional complexity, a multitude of neurologic dysfunction 
may ensue should the spinal cord become damaged in the event of traumatic injury. Details of 
specific functional anatomy, espeically those clinically relevant to locomotion and inter-limb 
coordination, sensory- and motor-evoked potentials, as well as lower urinary tract function, will 
be discussed in Chapters 3 – 6, in which the main outcome measures used in this clinical trial to 
assess various aspects of spinal cord function will be independently reported as separate studies.  
 
Pathophysiology of traumatic spinal cord injury  
Spinal cord injury consists of three chronological phases: (1) primary mechanical injury 
induced by traumatic forces such as contusion, compression and laceration that directly damage 
spinal cord parenchyma; (2) secondary injury starting immediately after the primary injury, 
characterized by intense inflammatory and ischemic processes that exacerbate the primary insult; 
and (3) chronic phase, occurring days to years post-injury, marked by cavitation and ‘glial scar’ 
deposition at the lesion epicenter13 – 18 (Figure 1.4).  
 
Figure 1.4 Phases of Spinal Cord Injury2,7. 
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Following the initial mechanical injury that damages neurons, neuroglia, axons, myelin 
sheath and vascular structures, a series of progressive molecular and cellular events, collectively 
known as the secondary injury, ensue; these processes include vascular and ischemic changes, 
free radical formation, ionic imbalances, glutamate excitotoxicity, apoptosis and generalized 
inflammatory responses, that can result in additional damage including neuronal death and are 
thus responsible for much of the debilitating effect of traumatic spinal cord injury15 – 21.  
Trauma-induced blood spinal cord barrier breakdown causes immediate hemorrhage, 
hypoperfusion and inflammation that is characterized by blood-borne leukocyte infiltration into 
the injured spinal cord parenchyma; clinically, the lesion epicenter consists predominantly of 
activated neuroglia and hemorrhagic-leukocytic infiltrates, interposed with debris of macerated 
cytoarchitecture2,22. While blood extravasation can damage neuronal soma and axons, the 
hemolysates, especially iron from erythrocyte breakdown, can also be neurotoxic23,24.  
The loss of adequate vascular supply further predisposes the spinal cord to ischemic 
injury, marked by cell edema, increased endothelial permeability, hemorrhage and infarction; 
this leads to cell death and triggers inflammatory cascades that recruit and activate leukocytes 
and neuroglia to release proinflammatory cytokines, such as interleukin-1beta or IL-1β, 
interleukin-6 or IL-6, tumor necrosis factor or TNF, and leukemia inhibitory factor or LIF, plus 
reactive free radicals15.  
The levels of reactive free radicals, such as superoxides, hydroxyl radicals, hydrogen 
peroxides, and nitric oxide, increase significantly after injury and they are primarily synthetized 
by microglia, macrophages and neutrophils25. Reactive free radicals target polyunsaturated fatty 
acids, which can in turn devastate neuronal cellular metabolism through means such as altering 
membrane function by triggering the peroxidation of cell membrane polyunsaturated fatty acid, 
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or lipid peroxidation, that produces aldehyde products capable of inactivating key metabolic 
enzymes such as ‘Na+/K+-ATPase’ that maintains neuronal resting membrane potential2,26.  
Impairment of normal cellular membrane mechanisms for maintaining the 
transmembrane balance of ions, especially Na+, K+ and Ca2+, raises the resting membrane 
potential of ~ -68 mV towards 0 mV and thus promote neuronal depolarization and excitability2. 
Hyperexcitability is exacerbated by injury-induced release of excitatory neurotransmitters; up-
regulation of excitotoxic neurotransmitters, such as glutamate, can be triggered by injury-
induced proinflammatory cytokines released by activated resident spinal cord neuroglia and 
leukocytes that have arrived at the lesion site by infiltration or extravasation2,15,18 – 21.  
Excitotoxicity is caused by excessive excitation of the glutamate receptors, such as 
NMDA or N-methyl-D-aspartic acid receptors, AMPA or α-amino-3-hydroxy-5-
methylisoxazole-4-propionate receptors and KA or kainic acid receptors, on neurons and 
neuroglia, which can lead to ionic imbalances, apoptosis and cell loss16,26. NMDA receptors 
activation favors Ca2+ influx through glutamate-gated ion channels on neurons and excess 
intracellular Ca2+ accumulation can lead to apoptosis and necrosis through mechanisms such as 
caspase activation and production of nitrogen free radicals26,27.  
Likewise, activation of AMPA receptors can also lead to excess intracellular Ca2+ 
accumulation by reversing the action of Na+/Ca2+ exchangers in the neuronal cell membrane, that 
normally export Ca2+ in exchange for Na+ import, and thus results in Ca2+ influx, plus the release 
of Ca2+ from their intracellular stores28. Furthermore, glutamate-receptor binding can disrupt 
ionic homeostasis by enabling excessive Na+ and Cl- influx through disruption of transmembrane 
ionic transport mechanisms such as the ‘Na-K-Cl co-transporter isoform 1’ or NKCC1; excess 
ions attract water into the cell and causes neurons to swell and degenerate26,29. 
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Moreover, spinal cord injury induces activation of various cell populations from several 
sources: (1) resident neuroglia within the spinal cord parenchyma, such as astrocytes and 
microglia; (2) peripheral circulation, such as neutrophils, monocytes and macrophages; and (3) 
adaptive immune response, such as B- and T-lymphocytes29. Neutrophils are the first leukocytes 
recruited to the site of injury and they release various oxidative and proteolytic enzymes, like 
myeloperoxidase and matrix metalloproteinase-9, which can intensify the inflammatory response 
and augment spinal cord parenchymal damage30,31.  
Monocyte-derived macrophages from peripheral circulation that are produced in the bone 
marrow infiltrate the lesion epicenter and phagocytize tissue debris of neurons, axons, neuroglia 
and myelin32. There are two main subtypes of macrophages found in the lesion epicenter, M1 
and M2; M1 macrophages appear soon after injury and persist to exert their phagocytic and pro-
inflammatory actions, while M2 macrophages tend to have the opposite effect on injury-induced 
inflammation as they secrete neuroprotective anti-inflammatory cytokines and chemokines33 – 35. 
The spinal cord resident microglia population undergoes transformation from the 
quiescent, ramified state to the deramified, amoeboid morphology; like bone marrow-derived 
macrophages recruited from peripheral circulation, activated resident microglia functionally 
polarize to adopt one of the two phenotypes: (1) pro-inflammatory M1 that induces the synthesis 
and release of additional proinflammatory cytokines and excitatory neurotransmitters such as 
nitric oxide, TNF-α and glutamate during the secondary injury phase to trigger neurotoxic 
responses such as apoptosis, necrosis and excitotoxicity, and (2) anti-inflammatory M2 that 
maintains homeostasis and promotes cell survival and axonal regeneration19,20,36. 
Similarly, the astrocyte population consists of functionally diverse subtypes and one of 
their main roles during secondary injury is to maintain homeostasis; as the lesion epicenter starts 
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to form cavitation as the result of ischemic injury, inflammatory responses and phagocytic 
activity of the macrophages and microglia, activated astrocytes migrate to the epicenter and 
arrange themselves into a cellular network lining the margin, which consolidates to form a dense, 
chondroitin sulfate proteoglycan-rich ‘glial scar’ surrounding the central cavity, or syrinx30,37 – 40. 
 
Glial scar formation after spinal cord injury  
The adult mammalian spinal cord has a very limited capacity for functional recovery after 
severe injury due to a combination of factors: (1) secondary injury that exacerbates the primary 
insult, (2) release of specific axon-inhibitory molecules like Nogo and myelin-associated 
glycoprotein from disrupted myelin membranes, and (3) formation of the glial scar that acts as a 
physical and molecular barrier between the injured and the intact spinal cord parenchyma, 
hindering axonal regeneration2,13,14,22,37,41,42. 
Glial scar formation is initiated by blood brain barrier or blood spinal cord barrier 
disruption and the subsequent exposure of central nervous system parenchyma to blood-borne 
molecules14. Particularly, the blood protein fibrinogen can leak into the parenchyma almost 
immediately post-injury to trigger glial scar formation through astrocyte activation and 
subsequent induction of Smad2 phosphorylation in astrocytes via the TGF-β/Smad signaling 
pathway; conversely, fibrinogen-depleted mice have reduced levels of active TGF-β, mitigated 
neuroglial activation and reduced chondroitin sulfate proteoglycan deposition post-injury42.  
Chondroitin sulfate proteoglycan, the main glial scar constituent, is up-regulated after 
spinal cord injury22,37,41,42. Activated astrocytes, macrophages and oligodendrocyte progenitors 
start depositing chondroitin sulfate proteoglycans such as neurocan and NG2 into the 
extracellular matrix < 24 hours and peak ~ 1 week, while others such as phosphacan and 
10 
 
brevican peak later at ~ 1 month; levels of up-regulated chondroitin sulfate proteoglycans can 
persist for months37,41,42. The glial scar, especially the chondroitin sulfate proteoglycans within it, 
can obstruct axonal extension to synapse with intact neurons, which can lead to axonal growth 
cone dystrophy or collapse, marked by the formation of bulbous axonal terminals that represent 
functional stagnation and permanent regeneration failure37 – 40.  
Interestingly, collapsed growth cones that have failed to from synapses do not undergo 
the expected degenerative processes such as synaptic atrophy and elimination; these terminals 
remain metabolically dynamic with normal mitochondrial and trans-Golgi network functions and 
sustained synaptic activities including endocytosis and retrograde transportation14,43,44. Recent 
evidence suggests that the dystrophic axonal growth cones may in fact be the newly formed pre-
synaptic terminals synapsing with neuroglia within the glial scar, which express NG2, a 
prevalent chondroitin sulfate proteoglycan45.  
It is hence possible that one mechanism, through which the glial scar inhibits axonal 
regeneration and synaptogenesis with neurons, is preferential synaptogenesis with chondroitin 
sulfate proteoglycan-expressing non-neuronal targets in the glial scar. Surprisingly, this 
apparently undesirable inhibitory effect of chondroitin sulfate proteoglycans is essential during 
central nervous system development.  
 
 
 
 
 
 
11 
 
Central Nervous System Plasticity: A Target for Assisted Regeneration 
 
Role of extracellular matrix in development 
Neuroplasticity, or the central nervous system’s ability to form new synapses or novel 
neuronal pathways in response to changes in its environment, is largely mediated by molecules 
within the extracellular matrix that surrounds the developing central nervous system parenchyma 
and undergoes significant compositional changes as it matures46,47. Structurally, the extracellular 
matrix provides a framework that maturing cells can migrate within, anchor to and become 
organized around; while functionally, it supplies a rich source of growth-promoting factors that 
facilitate neurogenesis, neuritogenesis, axonal pathfinding and synaptogenesis46,48 – 51.  
For instance, laminin is a very potent substance for guiding embryonic neuronal 
migration; in vitro, the laminin-coated membrane dramatically augments the migration of 
cortical neurons; conversely, when the laminin receptor subunits, namely integrin receptor 
subunits α3 and β1, on the neurons are antigenically blocked with specific antibodies, 
neuritogenesis is subsequently diminished51. In vivo, laminin is an extracellular matrix 
glycoprotein produced by astrocytes that guides axonal extension during development and 
regeneration of the corpus callosum in acallosal neonatal mice49,50.  
Extracellular matrix molecules also influence corticogenesis; changes in fibronectin 
expression, for example, influence neuronal migration and axonal extension in the developing 
cerebral cortex52. Fibronectin is abundant in the ‘preplate’ neuropil formed by the pioneer 
neurons born in the ventricular zone that have migrated radially to just beneath the pial surface; 
the cerebral cortex precursor or the ‘cortical plate’ then splits the preplate into ‘marginal zone’ 
and ‘subplate’49. Fibronectin, abundant in the preplate and its derivatives, guides the radial 
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migration of newborn neurons from the ventricular zone to the marginal zone, subplate and 
cortical plate as these layers mature49. Thus, the temporospatial distribution of certain 
extracellular matrix molecules can influence development by attracting the migrating neurons 
and extending axons towards their intended targets.  
Unsurprisingly, equally important are the inhibitory or repulsive cues that prevent 
aberrant neuronal migration, axonal projection and synaptogenesis, which could result in the 
formation of undesirable or even detrimental neuronal pathways. Through their repulsive action, 
chondroitin sulfate proteoglycans, direct neural crest cell migration along their programmed 
pathways during development53. After neurulation, neural crest cells detach from the neural tube 
to migrate lateroventrally, giving rise to various somatic cell types including osteoblasts, 
chondrocytes, melanocytes, as well as cells of the prospective peripheral nervous systems such 
as Schwann cells, sensory ganglia and sympathetic and parasympathetic ganglia54.  
In the mouse embryonic sclerotome that will later give rise to adult skeletal tissue, 
regions of chondroitin sulfate proteoglycan distribution and neural crest cell migration pathways 
are mutually exclusive; changes in chondroitin sulfate proteoglycan distribution in the 
sclerotome during development chaperone the migrating neural crest cells to their stereotypic 
destinations53. Conversely, disruption of embryonic chondroitin sulfate proteoglycans, with 
sodium chlorate or β-D-xyloside, enables neural crest cell to migrate along novel pathways 
within the dorsal portion of the somite that deviate from their natural lateroventral routes53.  
Hence, extracellular matrix molecules shape central nervous system development by 
influencing neuronal migration and axonal growth through both attractive and repulsive cues. 
Part of the reason that the immature central nervous system is capable of responding to these 
cues is their inherent plasticity, which becomes especially pronounced during the ‘critical 
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period’, a period during which exposure to the appropriate experiences governs the formation 
and organization of the correct neuronal networks55. 
 
Experiences shape development during the ‘critical period’ 
The immature central nervous system is particularly malleable during the critical period. 
For instance, postnatal development of the visual cortical circuity in kittens rely on exposure to 
visual stimuli 4 weeks – 3 months of age; as such, if vision is monocularly deprived during this 
period, the visual cortical layer IV territories that are normally innervated by the deprived eye via 
the geniculocortical afferents will shrink considerably, while areas that are usually innervated by 
the contralateral eye will reciprocally expand56,57. Simultaneously, there will be a shift in the 
pattern of visual cortical neurons’ responsiveness to stimuli, or ocular dominance, in favor of the 
visual input received by the non-deprived eye56,57. The same occurs in immature monkeys58. 
These findings suggest that visual cortical development is shaped by experience during the 
critical period. Interestingly, ocular dominance shift cannot be elicited in older animals58, 
implying that the critical period is perishable and once it has ended, plasticity diminishes and 
further experiences only have very limited impact on the established neuronal connections.  
 
Loss of plasticity during transition to adulthood  
As it matures, the mammalian central nervous system becomes increasingly refractory to 
experience-dependent reorganization; this cements function acquired during development, 
preserves established neuronal pathways, stabilizes functional synapses and prevents anomalous 
synaptic remodeling in response to subsequent experiences47,48, 59,60. This change in plasticity is 
largely driven by events that occur within the extracellular matrix; of particular significance is 
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deposition of the ‘perineuronal nets’ around neurons, whose main constituent is the ‘hyaluronan 
– lectican – tenascin-R’ ternary complex, organized around the chondroitin sulfate proteoglycan 
‘lectican’ (Figure 1.5) 55,59,61,62.  
 
Figure 1.5 Perineuronal Net Structure.  
Chondroitin sulfate proteoglycans are a family of proteoglycans consisting a protein core (single 
solid lines) and covalently linked chondroitin sulfate sugar or glycosaminoglycan side chains 
(blue hexagons), each consists of repeating disaccharide units. The lectican family (aggrecan, 
brevican, neurocan and versican) are a major component of the perineuronal nets. Lecticans have 
three regions: (1) a N-terminal G1 domain (pink triangles) that binds with the backbone of 
hyaluronan (double lines), an abundant extracellular matrix glycosaminoglycan, through link 
proteins (e.g. Bral-1 or HAPLN 2); (2) a side chain attachment region; and (3) a C-terminal G3 
domain (green squares) that binds with tenascin-R (Tn-R), one of the five extracellular matrix 
proteins in the tenascin family. This ‘hyaluronan – lectican – tenascin-R’ ternary complex forms 
the perineuronal nets that surround mature neurons within the adult central nervous system. 
 
Perineuronal nets emerge within the extracellular matrix relatively late during 
development towards the end of the critical period. Hamster spinal cord motor neurons, for 
instance, begin to lose their experience-dependent plasticity, induced by sciatic nerve lesion and 
thoracic spinal cord hemisection, when Cat-301-postive neurons appear around postnatal Day 7 – 
10; Cat-301 is a monoclonal antibody with specific affinity for the key perineuronal net 
constituent chondroitin sulfate proteoglycans55,61 – 63.  
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Quantitative immunostaining of rat visual cortex layers II – IV has revealed temporal 
changes in the expression levels and relative proportions of the main chondroitin sulfate 
proteoglycans between postnatal Day 7 and adulthood; while aggrecan, brevican and versican 
experience increases of variable magnitude, neurocan levels concurrently decline59. 
Accompanying changes in their levels during development are alterations in the disaccharide 
sulfation pattern of their side chains, with a remarkable shift from the 6-sulfated and 0-sulfated 
glycosaminoglycan to 4-sulfated glycosaminoglycan between postnatal Day 0 and adulthood59.  
Thus, it is possible that perineuronal net deposition towards the end of the critical period 
is driven by changes in the structure and composition of chondroitin sulfate proteoglycans during 
development, possibly in favor of the subtypes that are more plasticity-restricting. Other 
extracellular molecules, such as the ‘link proteins’ or Crtl1 that stabilizes intermolecular bonds 
within the extracellular matrix, could also influence the formation of perineuronal nets.  
Crtl1 mRNA levels rise dramatically around postnatal Day 14 in the mouse visual cortex 
layers II – III, coinciding with emergence of the perineuronal nets; conversely, genetically 
modified Crtl1-knockout adult mice develop disorganized, attenuated perineuronal nets and 
retain central nervous system plasticity beyond the natural critical period, such that a remarkable 
decline in visual acuity and a shift in ocular dominance can be induced by 3-day monocular 
deprivation, which would not ordinarily be possible after the critical period59. 
Similarly, plasticity persists beyond the natural critical period in the spinal cord of Crtl1-
knockout adult mice. One week following C6 – C7 unilateral dorsal hemisection that severs 
ascending sensory axons innervating the medial two digits of the ipsilateral forepaw, 
transganglionic cholera toxin B labeling reveals significant axonal sprouting into the lesioned 
area in the Crtl1-knockouts, but not in the controls59. Retention of plasticity well beyond the end 
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of the critical period in the absence of properly formed perineuronal nets thus raises the question: 
through which molecular mechanism(s) do perineuronal nets restrict plasticity?  
Interestingly, the effect of Crtl1-knockout on neuroplasticity is reminiscent of that of the 
bacterial enzyme ‘chondroitinase ABC’, which revives plasticity by digesting the chondroitin 
sulfate proteoglycan sugar side chains64 – 73. Early in vitro experiments suggest that Neu7, a 
neurite growth-inhibitory astrocyte cell line, secretes a heat stable, highly inhibitory extracellular 
matrix proteoglycan that is particularly sensitive to chondroitinase ABC-mediated side chain 
digestion71. When the proteoglycan-producing Neu7 astrocytes are treated with a proteoglycan 
synthesis inhibitor that results in under-sulfation of the proteoglycan and thereby reduces its side 
chain charge density, dorsal root ganglion axonal growth is noticeably enhanced72. These 
findings hence suggest that the side chains could be a key effector of axonal growth inhibition, 
albeit further investigations are warranted to establish this speculative causal relationship.  
In summary, the loss of central nervous system plasticity during development is likely 
due to changes within the extracellular matrix such as perineuronal net deposition; these changes 
hinder axonal regeneration after injury. Chondroitin sulfate proteoglycans are a family of 
inhibitory substances that impair axonal regeneration and functional recovery after spinal cord 
injury22,37,41,42; they are thus a plausible therapeutic target for interventions that are designed to 
promote axonal regeneration and functional recovery by reactivating neuroplasticity.  
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Clinical Translation of Chondroitinase ABC 
 
Experimental evidence in laboratory animal models   
Chondroitinase ABC is a commercialized bacterial enzyme, purified from Proteus 
vulgaris, that selectively deglycosylates chondroitin sulfate proteoglycans and removes the 
glycosaminoglycan side chains from its protein core, thereby disrupting perineuronal nets60,61,72 
(Figure 1.6). There is a growing body of experimental evidence that attests to the efficacy of 
chondroitinase ABC in promoting axonal regeneration and functional recovery after traumatic 
spinal cord injury by reactivating neuroplasticity. 
 
Figure 1.6 Chondroitinase ABC’s Mode of Action.  
Chondroitinase ABC (black arrows) removes side chains from the protein core. 
 
 
A 2002 study reports that through chondroitin sulfate proteoglycan degradation at the 
lesion site, chondroitinase ABC improves locomotor and proprioceptive functions, assessed by 
outcome measures like narrow metal beam crossing, wire grid test and footprint analysis, in 
experimental rats after C4 dorsal column crush injury; these functional improvements parallel the 
partial restoration of electrophysiological conductivity across the lesion as while the vehicle-
treated rats have no recordable cortical evoked cord dorsum potentials, they were present in the 
chondroitinase ABC-treated rats, albeit with a 60% decline in latency or conduction velocity 
compared to the sham-treated rats74.  
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The benefit of chondroitinase ABC is more pronounced when used as an adjunct 
treatment in a multimodal therapeutic approach. A 60-rat study suggests that while 
chondroitinase ABC on its own can enhance corticospinal axonal sprouting, remarkable 
improvement in manual dexterity only occurs when specific rehabilitation regimens are 
concurrently reinforced after C4 cut injury, measured by the number and accuracy of pellets 
retrieved, which doubles in the ‘chondroitinase + rehabilitation’ group compared to either 
intervention given alone67. This suggests that chondroitinase ABC-mediated plasticity 
reactivation and subsequent axonal sprouting work synergistically with rehabilitation training 
that reinforces and refines the regenerated synaptic pathways; the net result of this approach that 
simultaneously target multiple therapeutic pathways is augmented functional improvement.  
With advancement in biomedical technologies, chondroitinase ABC, thermo-stabilized 
with trehalose, can now be delivered in a temporally and spatially controlled manner using a 
hydrogel-microtube-based system75. This new chondroitinase ABC delivery system extends the 
in vivo chondroitin sulfate proteoglycan-suppressive effect of a single dose of chondroitinase 
ABC to up to 6 weeks post-treatment, which is associated with improved locomotor function in 
experimental rats measured by gait analysis 6 weeks after T10 hemisection75. This improved 
design eliminates the need for sustained chondroitinase ABC delivery through suboptimal 
conventional means such as repeated intrathecal injections or placement of indwelling catheters, 
thus rendering its administration more practical and its clinical translation more likely.  
More recently, a 2014 study reports a novel, extended delivery approach using gene 
therapy and a lentiviral vector to transduce the host cells to express chondroitinase ABC in 
experimental rats76. Compared with the conventional chondroitinase ABC-treated group, the 
lentiviral vector-chondroitinase ABC-treated group demonstrates more pronounced chondroitin 
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sulfate proteoglycan digestion and tissue bridge formation across the lesion epicenter 8 weeks 
after impactor-induced T10 – T11 contusion injury, and considerably reduced cavity formation 
and higher neuron count adjacent to the lesion epicenter76. Functionally, lentiviral vector-
chondroitinase ABC-treated rats have fewer horizontal ladder foot-slips at all weekly time-points 
up to 10 weeks post-injury; this parallels the concurrent improvement in cord dorsal column 
electrophysiological conductivity76. 
Surprisingly, new experimental evidence from a 2016 study suggests that the glial scar 
may aid axonal regeneration77. In this study, glial scar-forming astrocytes are genetically 
manipulated such that they would either (1) lose their ability to produce a normal glial scar in 
response to injury, or (2) form a glial scar that would only persistent for 5 weeks post-injury; in 
both scenarios, glial scar obliteration are associated with reduced axonal growth and more 
extensive tissue degeneration after T10 crush injury in mice77. How can we reconcile this novel 
finding with our long-held belief that the glial scar is axon-inhibitory?  
One of the reasons that generalized glial scar ablation seems to produce worsened 
outcomes could be that the ablation techniques utilized in this study lack functional selectivity. 
Concurrent RNA sequencing reveals that both astrocytic and non-astrocytic populations in the 
glial scar can produce growth-promoting molecules that aid axonal regeneration post-injury77. 
Hence, mass disruption of the glial scar may be counterproductive for axonal regeneration, as it 
could non-selectively eliminate both its growth-inhibitory and growth-promoting effects.  
It is also possible that several sub-types of astrocytes that reside within the glial scar, 
possessing reciprocal abilities of growth-promotion and growth-inhibition, may be concomitantly 
destroyed by generalized glial scar ablation and thus undesirably shifting the balance towards net 
axon inhibition. Thus, interventions that target specific molecular mechanisms, rather than 
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blanket-treat an entire cell population, may be more likely to produce desirable and predictable 
therapeutic effects and, perhaps even more importantly, fewer undesirable and unpredictable side 
effects, and subsequently undergo fruitful clinical translation.   
 
Challenges in clinical translation of chondroitinase ABC  
Clinical trials investigate the efficacy of putative interventions and indirectly assess the 
quality of the animal models from which the treatment response data have been derived. 
Encouragingly, numerous rodent studies have demonstrated chondroitinase ABC’s efficacy in 
promoting axonal regeneration and functional recovery after spinal cord injury. However, upon 
closer examination, there are some concerning elements, associated with both the animal models 
and the data generated from them, which may have distorted the true therapeutic effect of 
chondroitinase ABC and thus may impact on its clinical translatability.  
At least some aspects of functional improvement after chondroitinase ABC 
administration can plateau67,68,78, presumably when a certain critical point is reached. This raises 
the question of whether an adequate level of functional recovery could be achieved in patients 
before onset of this therapeutic plateau, after which further improvement would be improbable. 
There is also considerable inter-individual and inter-study variability in the magnitude of 
treatment response64,66,67,74,75,78, which warrants skepticism concerning the reproducibility of 
chondroitinase ABC’s reported therapeutic effect and thus its estimated translational value. 
Another related issue is the large number of outcome measures that are often used 
relative to study group sample size, which triggers concerns regarding statistical power and the 
possible occurrence of Type I error, or false positives arising from random probability. This is 
especially alarming when numerous hypotheses are tested using many outcome measures in a 
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study that contains multiple small groups. For instance, the well-cited and perhaps one of the 
better-powered studies, reporting the effect of chondroitinase ABC on forelimb function in 
spinal-injured rats with or without rehabilitation therapy, comprises four groups of 10 – 13 
subjects; while for motor function alone, seven outcome measures are reported in graphs and 
checked for significance68. Treatment effect data derived from inadequately powered studies 
could be misleading as the apparent statistical significance may more likely be the result of 
random probability rather than real therapeutic effect.  
Clinically, severe injuries, typically caused by spinal column fracture in people and 
intervertebral disc herniation in dogs, have elements of both contusion and compression, which 
can cause extensive primary mechanical damage and secondary injury (Figure 1.7). In contrast, 
experimental models, especially the earlier ones, often involve relatively mild, focal crushing or 
incisional injuries affecting < ¼ – ½ spinal cord cross-sectional area64,66 – 68,75,78; both primary 
and secondary injuries are thus considerably subdued compared to their clinical counterparts. 
Another consideration is that there may be significant delays, possibly days to weeks, 
before an intervention that requires intrathecal administration could be practically delivered, 
presumably by a trained specialist; while in animal models, chondroitinase ABC is often 
administered immediately or shortly after injury65 – 68,75. Since treatment effect data on chronic 
injuries are limited, it is possible that chondroitinase ABC’s clinical therapeutic effect, if any, 
may only benefit the subgroup with acute injuries. Further, disparity in the timing of drug 
delivery renders its clinical therapeutic window difficult to determine.  
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Figure 1.7 Magnetic Resonance Imaging of a 4-year-old Dachshund with Intervertebral Disc 
Herniation. Lesion epicenter is directly over L1 – L2 intervertebral disc space (middle dotted line 
in top left image) and the herniated disc material causes moderate to severe spinal cord 
compression (white arrow in top right image) at this level, markedly distorting the spinal cord 
outline, compared to one spinal cord segment cranial to the lesion epicenter (bottom images). 
 
 
Role of pet dogs as translational models in pre-human clinical trials 
Discrepancies between our current models and their clinical counterparts raise 
uncertainty regarding the generalizability of chondroitinase ABC’s treatment effect to clinical 
injuries, which could vary considerably due to injury and patient heterogeneity79. Like human 
patients, spinal-injured pet dogs vary substantially in age, size, genetics, lifestyle, concurrent 
medical conditions, injury chronicity and severity, plus their caretaker’s ability and commitment. 
Investigations conducted on pet dogs, through statistical means such as multivariate 
analysis, may hence help identify subgroups that are most likely to respond to the treatment 
and/or most susceptible to its potential side effects and assist with the development of 
personalized treatment strategies that are more likely to lead to successful clinical translation.  
A recent UK clinical trial in paralyzed pet dogs using autologous olfactory mucosal cell 
transplants80 highlights their practical utility as disease models in pre-human clinical trials, in 
addition to the more immediate veterinary application, should the potential therapy be proven 
effective. Additionally, the remarkable cost differential renders the clinical canine model 
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economically desirable. While the current costs of clinical trial enrollment in the United States 
and Europe are $50,000 – 100,000 per person, those of the veterinary trials are only fractional by 
comparison, unlikely to exceed several thousand dollars per animal81.  
 
Clinical trial phases  
Clinical trials are designed to evaluate the efficacy and safety of potential interventions 
and they are categorized into four phases: Phase I studies are typically open-label safety or pilot 
trials that are intended to uncover any adverse reactions of the interventions, especially those 
with narrow therapeutic indices; Phase II are blinded, controlled therapeutic exploratory studies 
that are designed to detect therapeutic effects in a narrow spectrum of patients using specific 
outcome measures; Phase III are therapeutic confirmatory studies, typically blinded, randomized 
and controlled, that definitively confirm Phase II results in a broader spectrum of patients; Phase 
IV studies involve long-term evaluation of benefit and harm in clinical settings following 
marketing approval by regulatory authorities82 (Figure 1.8).  
 
Figure 1.8 Clinical Trial Phases82. 
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Conclusion 
 
The disappointing long-term functional outcomes of severe, traumatic spinal cord injury 
in human and veterinary medicine can be attributed to a combination of factors including: (1) 
secondary injuries that exacerbate the primary mechanical insult; (2) formation of the axon-
inhibitory glial scar; (3) loss of inherent neuroplasticity after the critical period; and (4) lack of 
effective therapies for assisted functional recovery. Chondroitinase ABC is currently one of the 
most promising treatments because of its ability to reactivate neuroplasticity through chondroitin 
sulfate proteoglycan degradation and subsequently promote axonal regeneration and functional 
recovery in rodent models. As chondroitinase ABC enters the early phase of clinical translation, 
emphasis should be placed on selecting suitable animal models, such as spinal-injured pet dogs, 
that are both economical and representative of the natural disease processes, in which its 
treatment effect and pharmacodynamics can be thoroughly investigated.  
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CHAPTER 2 
CLINICAL TRIAL DESIGN 
 
 
Pre-study Planning 
 
Pre-study animal ethics and safety approval 
This study was approved by Institutional Animal Care and Use Committeeb and 
Institution Biosafety Committee (IBC) at Iowa State University to be conducted at Iowa State 
University College of Veterinary Medicine. Written consent was obtained from the owner of 
each participant before commencement of any procedures related to the clinical trial. The owner 
was informed regarding the investigational nature of the study, requirements concerning 
hospitalization and recheck visits, randomization and blinding, and the procedures used as 
outcome measures and the potential risks that they carried.  
 
Pre-study Phase I safety trial for chondroitinase ABC injection 
An open-label Phase I trial had been completed prior to the commencement this current 
study in which the safety of intrathecal injection of heat-stabilized chondroitinase ABC in pet 
dogs with chronic, severe spinal cord injury was assessed. Five dogs were recruited within ~ 3 
weeks through an alert placed on a website for owners of paralyzed pet dogs 
(http://www.dodgerslist.com/). All five dogs met the inclusion and exclusion criteria that would 
later be used for this current study (Figure 2.3). Each dog received chondroitinase ABC 
                                                
b IACUC log number 3-13-7526-K 
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intrathecally under fluoroscopy guidance; the total dose of 625 mU was equally divided between 
two spinal cord sites, the lesion epicenter and the presumed cranial margin of the central pattern 
generator in the lumbosacral intumescence at the L3 – L4 interspace11, 83 – 85 (Figure 2.6).  
The main goal of the safety trial was to determine if there was any evidence of 
neuropathic pain, such as hypersensitivity or allodynia, at or near the injection site, which can be 
associated with glial scar digestion and aberrant axonal sprouting. Outcome measures used were: 
(1) weekly physical and neurological examination, including von Frey sensory testing of skin 
over the dorsum until post-injection Week 8, and (2) owner questioning regarding possible 
adverse effects. No dogs exhibited evidence of adverse effects and several showed improved 
mobility, although this was not formally quantified in the study.  
 
Pre-study sample size calculation 
Enrolled patients were randomized at a ratio of 1:1 to (1) Intervention to receive 
intrathecal chondroitinase ABC with physical therapy or (2) Control to receive transcutaneous 
sham hypodermic needle insertion with physical therapy. To detect attainment of a certain level 
of performance, defined as 25% dogs in the Intervention group and 0% dogs in the Control group 
recovering thoracic-pelvic limb gait coordination measured by phase shift by Month 6c, a 
minimum of 48 dogs were required for the study86: 
 
In this formula, N represents the minimum number of subjects in each experimental 
group; P1 and P2 represent the proportion of detectable treatment effect in each of the two 
                                                
c Both Intervention and Control groups had 0% thoracic-pelvic limb gait coordination prior to 
intervention at the time of baseline data collection or Day 0.  
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equally sized groups, or Intervention and Control in this case; and C(p, power) is equal to 7.9 
when α = 0.05 and power = 80%86. Thus, a minimum of 24 were required in each arm: 
 
 However, a target of 60 dogs was set to (1) allow for a small proportion of dropout due 
to owner decision and/or unforeseen euthanasia or death; and (2) permit detection and improve 
estimation of more subtle treatment effects, especially those on spinal cord functions that would 
be less likely to recover after severe traumatic injury, such as lower urinary tract function.  
 
Pre-specified outcome measures 
Four pre-specified outcome measures were used in this study to assess various aspects of 
spinal cord function, including motor, sensory and autonomic. The primary outcome measure 
was thoracic-pelvic limb gait coordination measured by phase shift: Chapter 3d. The secondary 
outcome measures were: (1) presence of transcranial magnetic motor-evoked potentials in pelvic 
limbs: Chapter 4; (2) the most cranial level of somatosensory-evoked potentials recordable from 
the spinal cord: Chapter 4; and (3) urinary bladder compliance: Chapter 5.  
 
 
 
 
 
 
 
                                                
d Actually analysis deviated from this; details outlined in Chapter 3, Materials and Methods.   
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Patient Selection and Management 
 
Patient recruitment  
Client-owned pet dogs were recruited January 2014 – March 2016 via four main 
channels: (1) Lloyd Veterinary Medical Center’s and other websites (Figure 2.1); (2) social 
media including Facebook and Twitter; (3) television and press interviews; and (4) referral by 
veterinarians and rehabilitation centers. Study information and contact details were available on 
the websites and social media sites, and in the clinical trial brochure (Appendix Item A).  
 
Figure 2.1 List of Websites Advertising Clinical Trial 
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Patient selection  
Patient selection was carried out in four sequential steps (Figure 2.2). If a potential 
candidate had suitable signalment and clinical history such as traumatic spinal cord injury 
secondary to intervertebral disc herniation or vertebral column fracture based on the medical 
records provided by their regular veterinarian, including diagnostic imaging report or images, 
surgery and neurologic examination report, an in-person evaluation was offered for further 
assessment of eligibility (Figure 2.3). Neurologic examination and general physical examination 
were independently performed by a board-certified veterinary neurologiste and a veterinary 
neurology residentf. In addition to excluding any concurrent systemic or neurologic conditions 
that might confound data collection or interpretation, specific neurologic tests were performed to 
assess the severity and extent of the spinal cord injury.  
 
Figure 2.2 Clinical Trial Evaluation Process. 
 
In particular, spinal cord segmental reflexes in the thoracic limbs, pelvic limbs and 
perineum were tested to ensure that the injury was confined to T3 – L3 segments. The reflexes 
                                                
e Nick Jeffery BVSc, PhD, MSc, DipECVS, DipECVN, CertSAO, DipSAS, FRCVS 
f Hilary Hu BSc BVSc 
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tested included withdrawal reflexes, patellar reflexes, anal tone and reflex; panniculus reflex or 
‘cutaneous trunci cut-off’ was also determined, by pinching the paraspinal skin bilaterally 
starting from the level of L5 – L6 dorsal spinous processes using a pair of forceps to elicit 
bilateral contractions of the cutaneous trunci muscles, to further localize the level of spinal cord 
injury. Injury severity was determined by assessing the dog’s ability to ambulateg and the 
presence of conscious pain perception or ‘deep pain’h in the pelvic limbs and tail by crushing the 
nail bed, digit and tail with forceps in small dogs or pliers in larger dogs11,87 – 89. 
 
Figure 2.3 Clinical Trial Inclusion & Exclusion Criteria. 
 
Dogs that met all inclusion criteria and none of the exclusion criteria (Figure 2.3) were 
consecutively enrolled with written consent from their owners, with knowledge and 
understanding of various aspects of the clinical trial, including randomization, blinding, 
                                                
g A dog was considered ‘ambulatory’ if able to walk ten consecutive steps unaided without 
falling or the lateral aspect of any part of the foot or metatarsals touching the ground surface. 
h Deep pain response was considered present if the animal vocalized, turned its head to the 
source of the stimulus, or attempted to bite in response to the stimulus. 
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assessments and procedures that would be performed during the clinical trial, owner 
commitment, potential sources of risks and costs. The clinical trial involved four week-long 
visits Monday – Friday at Months 0, 1, 3 and 6, during which neurologic assessments were 
performed to detect treatment effects and possible adverse effects by comparing between 
Intervention and Control (Figure 2.4).  
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Figure 2.4 Clinical Trial Schedule.  
NJ = unblinded investigator Nick Jeffery; HH = blinded investigator Hilary Hu. 
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Participants were housed in Canine Wards at Lloyd Veterinary Medical Center with 
regular in-hospital patients. Daily treatment and assessment were performed by a qualified 
veterinariani with trained veterinary students. Physical therapy was supervised by a certified 
canine rehabilitation technicianj with trained veterinary students at Canine Rehabilitation Center, 
which involved twice-daily sessions with patient-tailored exercises depending on the 
rehabilitation technician’s assessment and recommendation. The sessions typically involved cart 
exercise, passive range of motion maneuvers, weight shifting, balancing exercise, standing-to-
sitting-to-standing exercise, pool exercises and underwater treadmill exercise (Figure 2.5).  
 
Figure 2.5 Physical Therapy. Clinical trial patient, 4-year-old Miniature Dachshund, doing pool 
exercises in Canine Rehabilitation Center. 
 
 
Patient Randomization 
 
A sealed, opaque envelope, containing a piece of paper labeled ‘Intervention’ or 
‘Control’, was opened during each patient’s Clinical Trial Visit 1 after all baseline data had been 
collected and immediately before the scheduled injection, such that each patient had 50% chance 
                                                
i Hilary Hu BSc BVSc 
j Joanna Hildreth CVT, CCRP 
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of being allocated to either Intervention or Control group. The envelopes were made up in three 
blocks of 20, each containing 10 of either Intervention or Control. Both the patient’s owner and 
the investigatork responsible for data collection remained blinded to experimental group 
allocation until the end of the 6-month clinical trial enrollment period and did not know the 
nature of the randomized block sizes until the trial had been completed  
 
 
Chondroitinase ABC Preparation and Delivery 
 
Chondroitinase ABC injection preparation  
Trehalose and microtubes used for preparing the injections were supplied by the 
Bellamkonda laboratory at Georgia Institute of Technology and Emory University (R102). 
Chondroitinase ABCl, freeze-dried upon arrival and stored at -80oC, was thawed ~ 15 minutes 
prior to reconstitution. In a laminar flow flood hood, 800 µL of 38% trehalose buffer was added 
to a 15 U chondroitinase ABC bottle and mixed thoroughly by shaking and turning until fully 
dissolved. The solution was divided into two equal 7.5 U, or 400 µL, aliquots and stored in a -80 
°C freezer until use. Since the microtubes begin releasing chondroitinase ABC immediately after 
loading, they were combined the night before injection; one 7.5 U chondroitinase ABC aliquot 
was removed from the -80 °C freezer, thawed and mixed with a 10 mg tube of dry lipid 
microtubes using micropipettes in a sterile laminar flood hood and mixed gently with a 
micropipette before stored overnight at 4 °C. Each 400 µL aliquot contained 7.5 U 
                                                
k Hilary Hu BSc BVSc 
l Chondroitinase ABC (Proteus vulgaris), produce code: AMS-E1028-10, AMSBIO, online order 
from http://www.amsbio.com 
35 
 
chondroitinase ABC per 10 mg microtubes; this was the total dose for each dog and was stored 
for a maximum of two weeks at 4 °C before use.  
 
Patient preparation for injections 
The entire anesthesia protocol, from pre-anesthesia assessment and pre-medication to 
monitoring and finally to post-general anesthesia recovery, was performed by the Anesthesia 
Service at Lloyd Veterinary Medical Center, comprising board-certified veterinary anesthetists, 
veterinary anesthesia residents and technicians. Prior to scheduled injections, the patient was pre-
medicated with intramuscular dexmedetomidine at 0.015 – 0.025 mg/kg and intramuscular 
butorphanol at 0.1 – 0.4 mg/kg. General anesthesia induction was achieved with a slow 
intravenous bolus of propofol at 5.5 mg/kg. The patient was intubated and maintained on 1 – 2.5 
% isoflurane with oxygen during the entire procedure with close monitoring. Once fully 
anaesthetized, the patient was transported to the Fluoroscopy Procedure Room and placed in left 
lateral recumbency and surgically clipped, between the levels of mid-thorax and wings of the 
ilium, before surgically scrubbed with alternating chlorhexidine and povidone iodine.  
 
Chondroitinase ABC delivery 
Following preparation, patient was positioned on the fluoroscopy table in right lateral 
recumbency. A dog that had been assigned to Intervention to receive chondroitinase ABC had 
percutaneous placement of 20 or 22 gauge spinal needles through the interarcuate ligaments at 
(1) the lesion epicenter and (2) the L3 – L4 interspace, where the cranial margin of the central 
pattern generator in the lumbosacral intumescence in dogs is presumed to be located11,83 – 85. 
36 
 
Local delivery of chondroitinase ABC was designed to revive functional neuronal sprouting or 
plasticity of the damaged axons and denervated target neurons. 
The spinal needles were advanced until they reached the vertebral canal ventral floor, 
which were guided by fluoroscopy and confirmed by observing cerebrospinal fluid dripping from 
the needle hub. Once the needles had reached the ventral floor, they were retracted a few 
millimeters to ensure intra-parenchymal placement; needle tip positions were confirmed on 
fluoroscopy (Figure 2.6). A total of 200 µL chondroitinase ABC solution was injected into each 
site via the spinal needles; at each site, 100 µL solution was injected with the bevel of the spinal 
needle facing cranially and 100 µL injected with the bevel facing caudally.  
 
Figure 2.6 Fluroscopy-guided Intrathecal Spinal Needle Placement.  
 
In Control patients, hypodermic needles were inserted at the same two locations 
transcutaneously to mimic the intrathecal chondroitinase ABC injections in order to maintain 
blinding of the owner and the blinded investigator. After either procedure, each patient was 
transported to Anesthesia Recovery for extubation and close monitoring until all vital parameters 
returned to normal, after which the patient was transported back to Canine Wards.  
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Summary Statistics 
 
A total of 196 potential candidates were evaluated, of which, 111 were excluded because 
their injury history was either unavailable or did not meet all inclusion criteria (Figure 2.7). Of 
the 85 that had eligible medical history and were thus offered in-person evaluations, a further 12 
were excluded because their owners either declined or failed to respondm. Seventy-three were 
evaluated in person and 13 were excluded because they did not meet all inclusion and exclusion 
criteria. The 60 dogs that fulfilled all criteria were consecutively enrolled in the study.  
 
Figure 2.7 Clinical Trial Enrolment. LMN = lower motor neuron signsn. 
 
                                                
m Each owner was contacted at least three times by phone or email before exclusion.  
nLower motor neuron signs (e.g. reduced or absent limb reflexes) would suggest that the spinal 
cord injury was extensive and thus unlikely to respond to focal chondroitinase ABC injection. 
  
38 
 
The 60-dog cohort consisted 29 females and 31 males, of which 31 were Dachshunds 
while the rest were small to medium breeds < 20 kg (Table 2.1). Intervertebral disc herniation 
was the cause of spinal cord injury in 48 and the remaining 12 had sustained traumatic vertebral 
column luxation or subluxation. Surgical intervention was implemented in 42 and 18 were 
managed conservatively with medication for cage-rest. At the time of baseline data collection at 
Day 0, 51 dogs were non-ambulatory and 54 had absent deep pain in their pelvic limbs and tail.  
 
Table 2.1 General Summary of 60 Participants. 
Sex Female 29 (48%)  
 Male  31 (52%) 
Breed  Dachshund   31 (52%) 
 Others  29 (48%) 
Cause  Intervertebral disc herniation  48 (80%) 
 Vertebral column fracture 12 (20%) 
Treatment  Surgery  42 (70%) 
 Conservative  18 (30%) 
Ambulationo Non-ambulatory  51 (85%) 
 Ambulatory  9 (15%) 
Deep painp Absent 54 (90%) 
 Present  6 (10%) 
Age (year)  
Mean/median/range 
6.2/6.0/0.5 – 14 
Weight (Kg) 7.6/6.1/2.2 – 20 
Chronicity (month) 23/14.5/3 – 89 
 
                                                
o A dog was considered ‘ambulatory’ if he/she was able to walk ten consecutive steps unaided 
without falling or the lateral aspect of any part of the foot or metatarsals touching the ground. 
p Deep pain response was considered present if the animal vocalized, turned its head to the 
source of the stimulus, or attempted to bite in response to the painful stimulus applied to the 
pelvic limb digits and/or tail. 
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Dogs that were classified as ‘ambulatory’ at Day 0 all had absent deep pain, suggesting 
that their spinal cord injuries were severe or complete, such that their pelvic limb ambulation was 
most likely mediated by injury-induced central pattern generator activation, or ‘spinal-walking’, 
rather than true recovery of locomotion; this is discussed in Chapter 3. These dogs typically 
shows poor inter-limb coordination, which can serve as a surrogate for change in neurologic 
function after receiving Intervention. Following baseline data collection, the participants were 
equally randomized to Intervention or Control with 30 in each group (Table 2.2).  
 
Table 2.2 General Summary of Intervention and Control. 
  Intervention Control 
Sex Female 15 (50%) 14 (47%) 
 Male  15 (50%) 16 (53%) 
Breed  Dachshund   13 (43%) 18 (60%) 
 Others  17 (57%) 12 (40%) 
Cause  Disc herniation  22 (73%) 26 (87%) 
 Vertebral column fracture 8 (27%) 4 (13%) 
Treatment  Surgery  21 (70%) 21 (70%) 
 Conservative  9 (30%) 9 (30%) 
Ambulation Non-ambulatory  25 (83%) 26 (87%) 
 Ambulatory  5 (17%) 4 (13%) 
Deep pain Absent 26 (87%) 28 (93%) 
 Present  4 (13%) 2 (7%) 
Age (year)  
Mean/median/range 
6.2/6.0/0.5 – 14 6.1/6.0/1 – 13 
Weight (Kg) 8.2/6.3/2.7 – 20 6.9/6.0/2.2 – 17 
Chronicity (month) 19.5/10.5/3 – 75 26.5/17/3 – 89 
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CHAPTER 3 
GAIT EVALUATION 
 
 
Introduction 
 
Traumatic thoracolumbar spinal cord injury in pet dogs, typically secondary to 
intervertebral disc herniation and vertebral column fracture, can cause varying degrees of 
locomotor impairment in the pelvic limbs, ranging from mild ataxia to paraplegia. 
Assessment of the gait, or synchronous limb locomotion in different stereotypic patterns 
including walk, trot, pace, amble and gallop, is an established functional parameter for 
investigating motor function impairment in thoracolumbar spinal-injured veterinary patients90 
– 94.  
Common gait assessment techniques in both human and veterinary medicine include: 
(1) temporal analysis to measure gait parameters, such as velocity, symmetry and relative 
stance and swing phase duration, by recording foot placement with apparatuses including 
force plates; (2) kinematics to study the relative movement of body or limb segments by 
means such as high-speed motion picture analysis and electrogoniometry; (3) 
electromyography to examine individual skeletal muscle activity; and (4) kinetics to evaluate 
the forces generated by a limb or within specific joints during locomotion90,95 – 100.  
Normal locomotion relies on continuous communication between central neural 
circuitries within the brain and spinal cord, and their sensory input including proprioceptive, 
vestibular, visual and auditory; the dynamic sensorimotor interaction confers flexibility and 
adaptability to locomotion in response to the evolving intrinsic and extrinsic stimuli101. 
Voluntary locomotion is initiated in the cerebral motor cortex and modulated in several brain 
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locomotor areas before the information descends in pyramidal and extrapyramidal tracts to 
reach spinal cord motor neurons. 
Three pyramidal tracts arise from the motor cortex of the dog: (1) corticonuclear tract 
that synapses with the ipsilateral cranial nerve nuclei as it descends in the crus cerebri, pons 
and pyramid; (2) corticopontine tract that synapses with ipsilateral pontine nucleus, which 
gives rise to the pontocerebellar fibers that decussate to reach the contralateral cerebellum; 
and (3) corticospinal tract that descends in the ipsilateral internal capsule, crus cerebri and 
pons before reaching the pyramid, where ~ 75% fibers decussate and ~ 25% remain 
ipsilateral to reach spinal cord motor nuclei that in turn trigger skeletal muscles to execute a 
certain effect via peripheral nerves102,103 (Figure 3.1).  
Extrapyramidal tracts, especially rubrospinal and reticulospinal tracts, whose nuclei 
originate in the red nucleus in midbrain and the reticular formation respectively, spanning 
from midbrain to medulla oblongata, modulate motor function initiated by the motor 
cortex102,103. The red nucleus communicates with forebrain and cerebellum via the olivary 
nucleus and mediates movement initiated by the motor cortex via the rubrospinal tract; while 
the reticular formation, through simultaneous stimulation and inhibition of spinal cord motor 
neurons that innervate limb extensors and flexors via pontine and medullary reticulospinal 
tract, respectively, coordinates stereotyped motor patterns such as spinal cord reflexes and 
gait patterns102,103. 
Two additional supraspinal centers are involved in locomotion: (1) the 
‘mesencephalic locomotor area’ in the dorsal reticular formation at the mesopontine junction; 
and (2) the ‘central pattern generator’, which is a diffuse neural network in the thoracolumbar 
spinal cord103 – 106. Further, the hypothalamus may also influence locomotion, possibly by 
augmenting mesencephalic locomotor area stimulation through summation, as electrical 
stimulation of the hypothalamus can elicit stepping in anesthetized rats; on the other hand, 
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stimulation of other brain areas, such as ventral layers of the dorsal colliculus, ventromedial 
midbrain and lateral tegmentum, can inhibit locomotion107,108. 
 
Figure 3.1 Motor Tracts in the Dog. Corticospinal tract (blue) arises from the motor cortex 
and descends ipsilaterally until reaching the pyramid, where fibers either continue 
ipsilaterally in the ventral corticospinal tract or contralaterally in the lateral corticospinal 
tract. Extrapyramidal tracts (red): rubrospinal and reticulospinal tracts originate in the red 
nucleus and reticular formation103. 
 
Quadrupedal gaits that require thoracic-pelvic limb coordination are executed by 
spinal cord central pattern generators under the direction of supraspinal centers; stimulation 
of the mesencephalic locomotor area, for instance, activates the reticular formation, which in 
turn influences the central pattern generator via reticulospinal tract to produce rhythmic, 
repetitive alternation between flexor excitation during ‘swing phase’ when the foot is mid-air 
and extensor excitation during ‘stance phase’ when the foot contacts the ground103,109,110.  
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Interestingly, the central pattern generator can produce locomotor patterns or ‘fictive 
patterns’ independent of supraspinal input following spinal cord injury by relying on 
peripheral sensory stimulation elicited by means such as tail crimping and perineal or pelvic 
limb stimulation111 – 114. While flexor afferent stimulation and transmission in one limb elicits 
discharge in ipsilateral spinal cord flexor motoneurons with simultaneous contralateral 
extensor motorneuron excitation, contralateral transmission of flexor afferent is concurrently 
inhibited114.  
Based on earlier experimental evidence, the reciprocal action of the motoneurons 
controlling the flexors and extensors in each limb has been postulated to be modulated by the 
segmental spinal cord interneurons that mediate mutual inhibition between motorneurons 
with reciprocal actions, or two ‘half-centers’, such that only half-center is active at a time; 
while inhibition of one half-center on the other is released when the former gradually 
becomes fatigued, triggering a ‘phase switch’ associated with the excitation of the latter114,115. 
However, this simplistic model of binary limb movement driven by dichotomous 
motoneuron activation fails to explain: (1) more complex locomotor patterns involving the 
sequential activation of various muscle groups in a limb during a step cycle, which are much 
more complicated and temporally stratified than the simple flexion-extension phase switch; 
and (2) activation of a subset of motoneurons in both swing and stance phases of a step 
cycle101,116. More sophisticated theories, attempting to explain the role of central pattern 
generator in orchestrating gait patterns, have since been proposed, however, the exact 
mechanisms remain elusive102,110,117,118.  
Experimentally, dogs and cats deprived of normal supraspinal locomotor control can 
be trained and/or stimulated to repetitively step and ambulate on a moving treadmill; these 
animals exhibit alternating pelvic limb flexion and extension resembling normal ambulation; 
however, they can only ambulate at lower speeds with a longer swing phase and weaker 
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stepping force in the pelvic limbs compared to normal animals, and show gait abnormalities 
like foot dragging and reduced angular stifle excursion111 – 113,119 – 125. 
The ability to regain locomotion appears to be particularly striking in first time-
injured neonates and repeat-injured adults such that the operates begin to show locomotion as 
early as 24 hours following complete caudal thoracic spinal cord transection98,121,124,126; this 
suggests that neuroplasticity, either inherent or injury-induced, activates spinal cord 
locomotor control in the absence of normal supraspinal input. Further, the spinal cord central 
pattern generator becomes more functionally complex and excitable over time, producing 
more diverse, complicated fictive patterns such as paw-shaking, stepping and strong rhythmic 
limb flexion when the paw is squeezed, in chronically spinal-injured animals112. 
Clinically, a subset of chronic, severe thoracolumbar spinal-injured pet dogs, typically 
with absent deep painq, can ambulate or ‘spinal-walk’ on their pelvic limbs; these dogs 
manifest distinctive pelvic limb locomotor characteristics that, from our direct clinical 
observation, resemble those described in experimental studies, including poor inter-pelvic 
and pelvic-thoracic limb coordination, high step cycle variability, foot dragging, lateral 
instability, reduced range of motion that is most noticeable in proximal joints like the stifle 
and hip, and speed limitation.  
These gait abnormities arise as the central pattern generator has a limited ability to 
precisely execute complicated locomotor patterns by relying solely on peripheral sensory 
input; the deficiency becomes more pronounced at higher ambulation speeds that normally 
require the recruitment of larger, faster pelvic limb motor units by supraspinal locomotor 
centers111,113,125,127,128. Gait parameters in spinal-injured dogs that manifest varying degrees of 
locomotor impairment, presumably dependant on the spinal cord tracts affected and extent of 
                                                
q Deep pain response, usually tested by squeezing the pelvic limb digits and tail with forceps 
or pliers, is a clinical neurologic test for determining the severity of spinal cord injury and its 
absence is associated with severe to complete spinal cord injury.  
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the damage, can thus be used as functional outcome measures to assess the magnitude of 
treatment effect of potential therapies for spinal cord injury129 – 131.  
Relatively simple, reproducible and cost-effective means of gait evaluation, such as 
treadmill gait analysis, can be very useful in clinical and translational spinal cord injury 
research as it allows the investigator to quantify the extent of neurologic deficits. Treadmill 
gait assessment can be done with a speed-adjustable treadmill and a number of cameras 
arranged around the treadmill for recording and relaying motion data while the test subject 
ambulates on the treadmill; both spinal-injured and spinal-intact dogs can learn to do so with 
little or no training80,91 – 94. Treadmill gait assessment has relatively high inter- and intra-
observer agreeability, rendering it a valuable tool, either used independently or in conjunction 
with other locomotor tests such as open field score, in multi-center clinical studies91. 
Specific gait analysis outcome measures can be utilized to evaluate the treatment 
effect of potential therapies on locomotor function by detecting functional changes in 
thoracolumbar spinal-injured dogs over time. These outcome measures include metrics for 
assessing inter-limb coordination such as the ‘stepping score’ or pelvic- to thoracic-limb step 
ratio, the ‘coordination score' or the proportion of pelvic limb steps that are coordinated and 
the ‘mean diagonal coupling interval’ that measures the temporal variability in pelvic limb 
placement responsible for thoracic-pelvic limb incoordination; other established gait metrics 
include the variability in step cycle duration, the temporal ratio of the swing to stance phase 
of a step cycle, and the lateral stability of pelvic limb paw placement80,91 – 94. 
We herein report the treatment effect of chondroitinase ABC on locomotion in 
severely spinal-injuredr pet dogs by comparing between Intervention and Control at baseline 
Day 0, followed by rechecks at Months 1, 3 and 6. Pelvic-thoracic limb coordination 
                                                
r 0% of the cohort showing pelvic-thoracic limb coordination when pre-intervention data was 
collected from Intervention and Control groups at Day 0. 
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measured by inverse of coefficient of variation (1/CV)s of the pelvic-thoracic limb phase shift 
while ambulating on a treadmill was used as the outcome.   
 
 
Materials and Methods 
 
Study approval, written consent, patient selection and chondroitintase ABC 
administration are outlined in Chapter 2. Eight infrared motion capture camerast mounted on 
adjustable tripods were arranged around and directed at the treadmill, four on either side. The 
recording field on the treadmill was calibrated with a T-shaped wand in accordance with 
instructions outlined in the Vicon Nexus user manualu before each treadmill gait recording 
session.  
The cameras recorded limb motion of the dog while ambulating on the treadmill by 
detecting the 10 mm reflective markers attached to ten pre-specified anatomic landmarks: (1) 
elbow joint at the lateral aspect of the proximal olecranon, (2) front paw at the lateral aspect 
of 5th digit, (3) stifle joint at the lateral aspect of proximal tibial tuberosity, (4) hock at the 
lateral aspect of proximal calcaneal tuberosity, and (5) lateral aspect of 5th digit of hind paw 
(Figure 3.2(a)). 
 
                                                
s CV = standard deviation/mean, 1/CV =  mean/standard deviation; a larger value means 
smaller data variability. Since variability is very small in spinal-intact dogs, 1/CV should 
increase in Intervention. 
t Motion capture cameras: 8-camera Bonita Vicon Motion Systems Ltd. UK. 
u Vicon Nexus user manual: Vicon Nexus 1.8.5, Vicon Motion Systems Ltd. UK. 
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(a) (b)  
(c) (d) 
Figure 3.2 Gait Recording. (a) Reflective markers taped to specific limb landmarks; (b) 
motion capture cameras mounted to tripods record limb movement of a marker-labeled dog 
walking on a moving treadmill with sling support; (c) camera input can be viewed in real-
time, along with camera positions labeled 1, 2 and 3; (d) markers can be manually labeled 
and joined to represent individual limb segments. 
 
Since most dogs were unable to ambulate and/or stand on their pelvic limbs, a sling, 
secured to the treadmill railing on either side, was placed underneath their caudal abdomen to 
provide weight support and as a safety measure to prevent injury in case the dog slipped and 
fell while ambulating; height of the sling was adjusted such that long axis of the dog’s back 
would be roughly parallel to the ground, as one would expect in a spinal-intact dog while 
standing (Figure 3.2(b)). 
Speed of the treadmill was adjusted such that the dog was able to leash-walk or 
harness-walk comfortably with the guidance and encouragement of an assistant. Speed 
selection for final gait analysis was based on two criteria: (1) the thoracic limbs must be 
advancing at an even pace with minimal speed variation during the recording; (2) the same 
speed must be used at all four time-points for the same dog. 
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At least one 1 – 2 minute recording(s) that qualified containing ~ 100 consecutive 
steps of each limb, or 6,000 – 12,000 frames, was obtained. When a dog ambulated, the 
cameras captured motion at a frequency of 100 frames per second and relayed this input via 
cable connections to a computer (Figure 3.2(c)). The input was viewed in real-time in Vicon 
Nexusv as a two dimensional representation of limb motion in a three-dimensional space that 
could be deconstructed into three planes or axes for analysis: (1) x-axis represented forward-
backward motion; (2) y-axis represented lateral motion; and (3) z-axis represented vertical 
motion.  
Data cleaning was done in accordance with Vicon Nexus user manualw. Briefly, 
markers at each pre-specified landmark were manually color-labeled and joined to form 
segments: elbow to fore paw, stifle to hock, hock to hind paw, and stifle to hind paw (Figure 
3.2(d)). Gaps in motion trajectories caused by unlabeled or missing markers were filled using 
the software-recommended trajectories, which were extrapolated from labeled trajectories of 
the same markers and their temporospatial relationships with other markers. After gap-filling, 
any additional unlabeled markers and trajectories were deleted before the recording was 
saved in several default formats; of which, the ‘.c3d’ format was exported to MATLABx for 
analysis.  
For coordination, z-axis or vertical motion was used. A ‘step’ was defined as when 
the paw height exceeded 10% of elbow height; timing of each step peak or when the paw was 
maximally raised was used for comparing the timing of the pelvic limb paw step peak in 
relation to the thoracic limb paw step peak that immediately preceded it, or ‘phase shift’. To 
minimize noise, exclusions were imposed such that any z-axis paw motion was excluded if: 
                                                
v Vicon Nexus 1.8.5 motion analysis software, Vicon Motion Systems Ltd. UK. 
w Vicon Nexus user manual: Vicon Nexus 1.8.5, Vicon Motion Systems Ltd. UK. 
x MATLAB R2015a (8.5.0.197613) 64-bit, The MathWorks Inc. 
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(1) it was < 10% elbow/stifle height; (2) its minimum peak prominence was < 0.75 cm; or (3) 
inter-peak time was < 0.25 second.  
Step cycle uniformity was used for selecting the reference limb such that whichever 
thoracic limb had a smaller step cycle variance was chosen, which was then matched with the 
contralateral pelvic limb. Thoracic-pelvic limb phase shift analysis was done by extracting, 
for each step within a 1 – 2 minute recording, the time difference or ‘phase shift’ between 
two time-points: (1) when the reference thoracic paw had its maximum z-axis value (i.e. 
maximally raised in the air) and (2) when the corresponding pelvic paw had its maximum z-
axis value.  
The phase shift of every step was extracted for each recording that contained a 
sufficient number of pelvic limb steps, or > 20% thoracic steps in the same recording. The 
mean and standard deviation of the phase shifts of each recording was used to calculate the 
inverse of coefficient of variation (1/CV)y that quantified data variability in relation to the 
population mean (i.e. larger 1/CV = smaller variability)z.  
Statistical analysisaa for pelvic-thoracic limb phase shift was done by using cross-
sectional time series regression with inclusion of baseline values as a covariate to allow for 
differences when the participants were enrolled. This method of analysis deviated from the 
original design outlined in Chapter 2 as the pre-study sample size calculation was based on a 
categorical outcome (i.e. 25% Intervention animals would regain coordination), while the 
actual outcome of phase shift (1/CV) was continuous. A similar previous study using 
continuous outcome measures had used a similar sample size to that calculated here80. 
  
                                                
y Coefficient of variation = standard deviation/mean, 1/CV = mean/std. deviation. 
z Since variability is expected to be very small in spinal-intact dogs, 1/CV should increase 
over time in Intervention group as phase shift becomes more uniform. 
aa Statistical analysis was performed by Dr. Nick Jeffery using Stata 11 Data Analysis & 
Statistical Software, StataCorp LP, College Station, TX. 
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Results 
 
Sixty dogs were recruited but data were not available from all at all time-points due to 
patient dropout and missed rechecks (Table 3.1). Pre-intervention baseline was collected at 
Day 0 from 60/60 patients in Intervention and Control; at Month 1, data were available from 
58/60; at Month 3, from 55/60; and at Month 6, from 52/60. General summary of 
Intervention and Control are reported in Chapter 2. 
 
Table 3.1 Data Availability for Gait Evaluation. 
Time/Group Intervention Control 
Baseline 30 30 
Recheck 1 29 29 
Recheck 2 27 28 
Recheck 3 27 25 
 
Gait coordination was assessed at the four time-points and compared between 
Intervention and Control, resulting in eight groups (Table 3.2, Figure 3.3). After excluding 
recordings in which < 20% thoracic limb steps were matched by pelvic limb steps, 198/224 
data-points were available for analysis. Shapiro-Wilk Wbb test showed that none of the eight 
groups except Control Recheck 2 was normally distributed. 1/CV of phase shift varied 
substantially amongst the cohort ranging from 1.4 to 43.7, but the medians, 2.1 – 2.3, were 
similar across all groups. 
 
 
 
 
                                                
bb JMP 11.0.0 (64-bit), 2013, SAS Institute Inc. 
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Table 3.2 1/CV of Pelvic-thoracic Limb Phase Shift. 
Group Q25 Median Q75 
Control Baseline 2.0 2.2 2.5 
Control Recheck 1 2.0 2.2 2.6 
Control Recheck 2 2.0 2.1 2.4 
Control Recheck 3 1.9 2.2 2.7 
Intervention Baseline 2.1 2.3 2.6 
Intervention Recheck 1 2.0 2.2 2.5 
Intervention Recheck 2 1.8 2.1 2.5 
Intervention Recheck 3 2.0 2.1 3.0 
 
 
Figure 3.3 1/CV of Pelvic-thoracic Limb Phase Shift. 
Control = Groups 1, 3cc, 5 and 7; Intervention = Groups 2, 4, 6 and 8. 
 
Following log transformation to mitigate the highly skewed distribution, statistical 
analysis showed 1/CV of phase shift was unaffected by group and chronicity; thus neither 
chondroitinase ABC administration nor injury chronicity had a significant effect on pelvic-
thoracic limb coordination (Table 3.3). Baseline had a significant effect with P = 0.00, i.e. 
dogs tend to maintain the same level of pelvic-thoracic limb coordination measured by 1/CV 
over the duration of the study. 
 
                                                
cc Data-point from Subgroup 3 with the value of 43.7 was excluded as an outlier.  
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Table 3.3 Statistical Summary of Log-transformed 1/CV of Coordination. 
Parameter  Coef Std Err z P>[z] 95% CI 
Study Group 0.05 0.04 1.08 0.28 -0.04 – 0.13 
Injury Chronicity 0.01 0.02 0.48 0.64 -0.03 – 0.04 
Baseline 0.78 0.07 10.73 0.00 0.34 – 0.93 
 
 
 
Discussion 
 
Analysis of gait coordination, measured by 1/CV of pelvic-thoracic limb phase shift, 
revealed that chondroitinase ABC has no statistically detectable treatment effect on 
locomotor function. Failure to regain pelvic-limb gait coordination in the chondroitinase 
ABC-treated Intervention group does not support our original hypothesis that pelvic-thoracic 
limb gait coordination would improve, quantified by an overall increase in 1/CV of pelvic-
thoracic limb phase shift.  
Since quadrupedal gaits that require thoracic-pelvic limb coordination are executed by 
spinal cord central pattern generators under the direction of supraspinal centers via pyramidal 
and extrapyramidal tracts103,109,110, our results suggests that the current drug formulation 
and/or delivery was unsuccessful in restoring the functional continuity of these supraspinal 
and spinal pathways. 
Nevertheless, our current method for analysing and quantifying gait coordination 
provides a novel means for assessing inter-limb phase shift. Our method offers a more 
detailed, sensitive analytic compared with some of the more conventional metrics for 
assessing inter-limb coordination such as the pelvic-thoracic step ratio and the proportion of 
coordinated pelvic limb steps; it also provides a straight-forward alternative to the more 
advanced gait metrics such as the ‘mean diagonal coupling interval’ that measures the 
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temporal variability in pelvic limb placement and the lateral stability of paw placement80,91 – 
94. 
One key limitation is the large number of data-points excluded for analysis. For 
pelvic-thoracic limb phase shift, 11.6% of the available data-points were excluded because 
the number of pelvic limb steps were < 20% of the corresponding thoracic steps, which had 
been recorded from study participants with lower levels of pelvic limb motor function. This 
method of selection could have created a certain degree of sampling bias, or more specifically 
exclusion bias, that would have favored individuals within the cohort that possessed superior 
motor function. On the other hand, inclusion of animals that had very few pelvic limb steps 
would have led to an inaccurate estimate of 1/CV of pelvic-thoracic limb phase shift based on 
a very small number of samples from each gait recording.  
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CHAPTER 4 
ELECTROPHYSIOLOGIC EVALUATION 
 
 
 
Introduction 
 
Electrophysiologic techniques can help evaluate the functional integrity of neurologic 
pathways and in spinal cord injury research, electrophysiologic parameters for spinal cord 
conduction can be used as minimally invasive, inexpensive outcome measures for monitoring 
post-injury functional recovery and quantifying the treatment effects of potential 
interventions. Transcranial magnetic motor-evoked potentials or TMMEPs and 
somatosensory-evoked potentials or SSEPs are two of the most well-established 
electrophysiologic techniques in humans and animals for evaluating the functional integrity 
of motor and sensory spinal cord pathways, respectively80,132 – 139. 
Both techniques involve applying an external stimulus, magnetic or electrical, to elicit 
transmembrane ion movement or current flow that depolarizes the neuron and triggers action 
potentials to travel along the spinal cord; the characteristics of action potential propagation 
can be quantified using parameters such as ‘onset latency’ or the time it takes for the nerve 
impulses to reach a certain location along the neurologic pathway, and ‘waveform amplitude’ 
or magnitude of the response elicited140.  
Somatosensory-evoked potentials, elicited by tibial nerve electrical stimulation and 
recorded from dorsal lamina of the vertebral body, can be used to evaluate ascending sensory 
pathways in dogs with acute spinal cord injury secondary to intervertebral disc extrusion139. 
One study shows that the potentials recorded from injury-adjacent T10 – T11 segments differ 
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considerably from the controls; further, waveform can serve as a reliable prognostic indicator 
for neurologic recovery, defined as regaining ambulation and urinary continence139. 
Similarly, scalp recording of somatosensory-evoked potentials from the contralateral sensory 
cortex can be used for monitoring change in spinal cord conduction following therapeutic 
intervention in spinal-injured pet dogs in a clinical trial setting80.  
Tibial nerve stimulation-evoked potentials recorded from the spinal cord are thought 
to be the ascending potentials generated by the ipsilateral proximal dorsal root, dorsal 
funiculus and afferent collaterals to the dorsal horn; this occurs when the ascending action 
potentials arrive following synaptic modulation within the lumbosacral intumescence in L4 – 
S3 segments in the dog11,141,142.  
Selective spinal cord transection studies suggest that while the ascending potentials 
propagate in all cross-sectional areas of the spinal cord, the ipsilateral dorsal quadrant, 
especially dorsolateral fasciculus and dorsal column, has the greatest contribution143. While 
onset latency is strongly correlated with body length in dogs, the correlation between 
amplitude and body length is only moderate144.  
Transcranial magnetic motor-evoked potentials, the counterpart of somatosensory-
evoked potentials, examine the functional integrity of spinal cord motor pathways. The 
potentials are elicited, in accordance with Faraday’s law of electromagnetic induction, when 
the magnetic coil-induced transitory magnetic field generates electrical impulses in the motor 
cortex, which is propagated along the spinal cord motor pathways to reach the periphery, 
such as cranialis tibialis and extensor carpi radialis muscles in the contralateral limbs, from 
which compound muscle action potentials are typically recorded138,140.  
In humans, the magnetic field-induced action potentials descend primarily in 
corticospinal pathways145, while in veterinary species such as rats and cats, extrapyramidal 
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tracts, including reticulospinal and vestibulospinal tracts, play larger roles in the propagation 
of transcranial magnetic motor-evoked potentials146,147. Similar to somatosensory-evoked 
potentials, quantifiable parameters of motor-evoked potentials, such as onset latency and 
amplitude, can be extracted from pet dogs in clinical studies as objective outcome 
measures93,137. 
In this study, we used (1) the cranial-most vertebral body level at which 
somatosensory-evoked potentials could be recorded and (2) the presence of transcranial 
magnetic motor-evoked potentials in pelvic limbs as outcome measures for assessing the 
therapeutic effect of chondroitinase ABC on restoring the electrophysiological integrity of 
sensory and motor pathways in severely spinal-injured dogs. Pre-intervention data were 
collected on Day 0 from Intervention and Control groups, followed by three rechecks at 
Months 1, 3 and 6.  
We hypothesized that Intervention group would have a smaller distance, measured in 
the number of spinal cord segments, between the caudal level of injury and the cranial-most 
level of recordable somatosensory-evoked potentials (Figure 4.1). The rationale of using this 
distance as an outcome measure is that chondroitinase ABC, a drug with the putative effect of 
promoting axonal regeneration, should theoretically promote spinal cord conduction across 
the lesion, such that the distance would be expected to decrease over time. 
 
Figure 4.1 Distance Measured in Number of Spinal Cord Segments. 
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We also hypothesized that Intervention would have a larger number of animals with 
recordable transcranial motor-evoked potentials in the pelvic limbs than Control at Months 1, 
3 and 6. The proportion of animals with positive pelvic limb transcranial magnetic motor-
evoked potentials was expected to increase in the Intervention group over time since 
chondroitinase ABC is thought to promote axonal regeneration and thus, theoretically, should 
restore functional continuity of the injured spinal cord. 
 
 
Materials and Methods 
 
Study approval, written consent, patient selection and chondroitinase ABC 
administration are outlined in Chapter 2. Following evaluation of vital parameters including 
heart rate, respiratory rate, mucous membrane color, capillary refill time and rectal 
temperature, each dog was sedated with 0.005 mg/kg dexmedetomidine and 0.2 mg/kg 
butorphanol intravenously. During the procedure, the dog was placed in sternal recumbency 
and monitored using the same vital parameters every 5 minutes until the end, when 0.05 
mg/kg atipamezole was given intramuscularly to reverse the effect of dexmedetomidine and 
the dog was ambulatory.  
Somatosensory-evoked potentials were recorded on a conventional electrodiagnostic 
unitdd from the dorsal lamina immediately cranial to dorsal spinous process using a bipolar 
recording electrodeee (Figure 4.2). Reference bipolar electrodeff was placed in the epaxial 
muscle ~ 1 cm lateral to the recording electrode ipsilateral to the side of stimulation. 
                                                
dd Nihon Kohden Neuropack M1 MEB-9200 EMG/EP/IOM System, discontinued 
ee Recording electrode: Ambu Neuroline Concentric 38 x 0.45 mm, Ref. 74038-45/25 
ff Reference electrode: Ambu Neuroline Concentric 38 x 0.45 mm, Ref. 74038-45/25 
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Subdermal ground electrodegg was placed subcutaneously over cranial aspect of the stifle 
joint. To minimize noise, pelvic limbs were minimally stimulated with subdermal needleshh 
placed near the tibial nerve at the hock; stimulation was confirmed by observation of slight 
digital twitching.  
 
Figure 4.2 SSEP and TMMEP Recording. Somatosensory-evoked potentials (left) recorded 
from L5 – L3 dorsal laminae; note amplitude attenuation at each recording site. Transcranial 
magnetic-evoked potentials (right) recorded from contralateral thoracic and pelvic limbs. 
Arrows indicate onset latency. 
 
Somatosensory-evoked potentials were considered present if the same waveform with 
a peak-to-peak amplitude of > 0.15 µV could be repeated at least once; amplitude and latency 
were recorded after signal averaging of > 200 sweeps. On each side, the recording started at 
L6 and progressed cranially one vertebra at a time until potentials could no longer be 
recorded; location, amplitude and latency of the potentials at the cranial-most vertebra were 
recorded for analysis. The vertebra immediately cranial to the level of spinal cord injury was 
tested to confirm loss of conduction across the lesion epicenter.  
                                                
gg Ground electrode: Ambu Neuroline Subdermal 12 x 0.40 mm, Ref. 74512-100/24 
hh Stimulating electrodes: Ambu Neuroline Subdermal 12 x 0.40 mm, Ref. 74512-100/24 
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Transcranial magnetic motor-evoked potentials were tested by stimulating the motor 
cortex at 70 % and 80 % stimulation intensities with a magnetic coilii held 1 – 2 cm from the 
skull and recording from the contralateral cranialis tibialis muscle with a bipolar recording 
electrodejj (Figure 4.2). Extensor carpi radialis muscle potentials recorded from the right 
thoracic limb served as control to ensure that a response could be elicited in an unaffected 
limb. Subdermal ground electrodekk was subcutaneously placed over the cranial aspect of the 
stifle. Response was considered present if three consecutive potentials with an amplitude of > 
0.15 mV were obtained from three separate stimulations at either intensity. Due to time 
constraint, only amplitude and latency of the last waveform were recorded. 
For both somatosensory-evoked and transcranial magnetic motor-evoked potentials, 
onset latency was defined as the time difference between Time 0 and onset of deflection from 
the baseline in either positive or negative direction; peak-to-peak amplitude was defined as 
the difference between two largest peaks of adverse polarity following the initial deflection 
from baseline. Statistical analysisll for the presence of pelvic limb motor-evoked potentials 
was done to detect any treatment effect associated with chondroitinase ABC by using time 
series logistic regression with the inclusion of time (Day 0, Month 1, 3 and 6) and baseline 
values as covariates; inclusion of the latter was to allow for differences when the participants 
were enrolled in the study.   
 
 
                                                
ii Magstim 2002, The MAGSTIM Company Limited, Whitland, Wales, UK.    
jj Recording electrode: Ambu Neuroline Concentric 38 x 0.45 mm, Ref. 74038-45/25 
kk Ground electrode: Ambu Neuroline Subdermal 12 x 0.40 mm, Ref. 74512-100/24 
ll Statistical analysis was performed by Dr. Nick Jeffery using Stata 11 Data Analysis & 
Statistical Software, StataCorp LP, College Station, TX. 
. 
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Results 
 
Sixty dogs were recruited but results were not available from all of them at all time-
points because of patient dropout, missed rechecks, and inability to perform procedure due to 
animal’s behavioural issues or technical difficulties (Table 4.1). Pre-intervention baseline 
data were collected at Day 0 from 60/60 patients between Intervention and Control; at 
Rechecks 1, 2 and 3, data were available from 58/60, 55/60 and 52/60. General summary data 
of the two groups are reported in Chapter 2. 
 
Table 4.1 Data Availability for Electrophysiologic Evaluation. 
 Sensory-evoked Motor-evoked 
 Intervention Control Intervention Control 
Baseline 27 30 30 30 
Recheck 1 28 29 29 29 
Recheck 2 27 28 27 28 
Recheck 3 27 24 27 25 
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For somatosensory-evoked potentials, the distance, measured in the number of spinal 
cord segments, between the caudal level of spinal cord injury and the cranial-most level of 
recordable potentials, was calculated and compared between Intervention and Control at the four 
time-points, resulting in eight groups (i.e. Control Baseline, Recheck 1, Recheck 2 and Recheck 
3; Intervention Baseline, Recheck 1, Recheck 2 and Recheck 3). The median distance was 
similar across all groups and remained the same for both groups during the study period; the four 
Control groups all had a median of 2 spinal cord segments and the four Intervention groups all 
had a median of 3 (Table 4.2). For the entire cohort, the distance ranged between -5 and 6 
segments. Where the potentials were not recordable, mostly due to excessive background noise 
levels, the number 15 was assigned to graphically reflect these data points (Figure 4.3). 
 
Table 4.2 Distance of Somatosensory-evoked Potentials (No. of Cord Segments). 
Group Q25 Median Q75 
Control Baseline 1 2 4 
Control Recheck 1 0 2 3 
Control Recheck 2 1 2 4 
Control Recheck 3 1 2 4 
Intervention Baseline 1 3 5 
Intervention Recheck 1 1 3 4 
Intervention Recheck 2 2 3 4 
Intervention Recheck 3 2 3 4 
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Figure 4.3 Comparison of Distance for Somatosensory-evoked Potentials.  
Animals from which potentials could not be recorded were assigned 15.  
Control = Groups 1, 3, 5 and 7; Intervention = Groups 2, 4, 6 and 8. 
 
Transcranial magnetic motor-evoked potentials were evaluated at each recheck and 
compared with Baseline at Day 0, where 3/30 of Control and 3/30 Intervention participants had 
recordable pelvic limb potentials; at Recheck 1, 5/29 Control and 6/29 Intervention did; by 
Recheck 2, 5/28 Control and 3/27 Intervention did; and at Recheck 3, the numbers were 3/25 and 
4/27 for Control and Intervention, respectively (Figure 4.4). Statistical analysismm showed that 
neither group (Intervention or Control) nor time (Day 0, Month 1, 3 and 6) had a significant 
effect on the presence of pelvic limbs motor-evoked potentials; albeit baseline appeared to have a 
significant effect on the outcome with P = 0.003, i.e. dogs that had recordable potentials at the 
start of the study were more likely to still have them at the end (Table 4.3). 
                                                
mm Stata 11 Data Analysis & Statistical Software, StataCorp LP, College Station, TX. 
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Baseline Recheck 1 Recheck 2 Recheck 3
Intervention 10.00% 20.70% 11.10% 14.80%
Control 10.00% 17.20% 17.90% 12.00%
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Figure 4.4 Proportion of Positive Motor-evoked Potentials. 
 
Table 4.3. Statistical Summary of Pelvic Limb Motor-evoked Potentials. 
Parameter  Coef Std Err z P>[z] 95% CI 
Study Group 0.32 0.88 0.36 0.72 -1.41 – 2.05 
Time -0.40 0.37 -1.09 0.28 -1.12 – 0.32 
Baseline 4.61 1.55 2.97 0.00 1.57 – 7.65 
 
 
 
Discussion 
 
The distance, measured in the number of spinal cord segments, between the caudal level 
of spinal cord injury and the cranial-most level of recordable sensory-evoked potentials remained 
the same during the six-month study participation period for both Intervention and Control. 
Chondroitinase ABC also had no treatment effect on the number of participants from which 
motor-evoked potentials were recordable from the pelvic limb. 
One potential source of bias would be the variable effect of sedation agents used, namely, 
butophanol and dexmedetomidine. While poorly investigated in veterinary medicine, human 
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studies report variable effects of these pharmacological agents on the recorded evoked potentials. 
For example, opioids, such as fentanyl, sufentanil and alfentanil, are shown, in various degrees, 
to decrease the amplitude and increase the latency of evoked potentials148 – 150. By contrast, 
dexmedetomidine, an alpha-2 receptor agnostic, appears to promote good conditions conducive 
to evoke-potential monitoring and has a negligible effect on the waveform amplitude151 – 152. 
Thus, it is possible that the effect of the sedation agents confounded the results collected 
due to differences in, for instance, the pharmacodynamics of individual participants. On the other 
hand, this confounding factor might have been mitigated in the current study as we only 
compared the presence and absence of evoked potentials as a gross assessment for detecting any 
potential treatment effect of chondroitinase ABC, and did not further carry out detailed 
comparison of the amplitude and latency of individual waveforms.  
Further, after confirming reproducibility, only one reading of the amplitude and latency 
of the last recorded waveform were measured for analysis due to time constraint, since we had to 
perform sensory-evoked and motor-evoked potential recording then manually measure the 
amplitude and latency on the conventional electrodiagnostic unitnn within the 30 minutes of 
reliable, adequate sedation. Measurement of multiple waveforms recorded from the same 
individual may be more time-effectively obtained on newer electrodiagnostic units
                                                
nn Nihon Kohden Neuropack M1 MEB-9200 EMG/EP/IOM System, discontinued 
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CHAPTER 5 
CYSTOMETRIC EVALUATION 
 
 
Introduction 
 
Persistent lower urinary tract dysfunction can be debilitating in spinal-injured human 
and veterinary patients. Both bladder filling and voiding are affected in T3 – L3 spinal-
injured pet dogs: during filling, spontaneous detrusor contraction, or ‘detrusor overactivity’, 
periodically elevates intravesical pressure and causes urine leakage. During voiding, 
uncoordinated detrusor and sphincter contraction, or ‘detrusor-sphincter dyssynergia’ causes 
ineffective bladder emptying153. 
Normal bladder filling and voiding are coordinated by both segmental spinal cord 
reflexes and supraspinal centers. During filling, gradual bladder distention stimulates the 
bladder wall mechanosensitive A-delta and C-fibers that in turn stimulate: (1) sympathetic 
innervation via hypogastric nerves to simultaneously contract the bladder outlet and inhibit 
the detrusor, and (2) somatic innervation of the external urethral sphincter via pudendal 
nerves; these mechanisms facilitates urine storage and prevents leakage11,103,153 – 156 (Figure 
5.1(a)).  
Although the pontine storage center may facilitate involuntary sphincter control, 
bladder filling is largely an involuntary process regulated by sympathetic thoracolumbar and 
somatic sacral segmental spinal cord reflexes in normal individuals103,156 – 159. In contrast, 
micturition is an active, voluntary process coordinated by supraspinal centers that ensure 
reciprocal detrusor contraction and outlet relaxation occur simultaneously when socially 
appropriate (Figure 5.1(b)). 
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Figure 5.1. Neurologic Control of Bladder Storage (a) and Voiding (b). 
 
Once a certain intravesical pressure or volume threshold, 12 – 32 cmH2O in conscious 
humans155,160,161 and 18 mL/kg or 50 cmH2O in anaesthetized dogs162, is reached, action 
potentials are triggered in the bladder wall afferent to convey this information to the pontine 
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micturition center and cerebral cortex157 – 159,162. Activation of the former simultaneously: (1) 
inhibits sympathetic and somatic innervation to trigger outlet relaxation, and (2) stimulates 
parasympathetic innervation to initiate and sustain detrusor contraction until urine voiding is 
complete. 
Lower urinary tract dysfunction as the result of traumatic spinal cord injury, affecting 
urine storage and/or voiding, can result from damage anywhere within the micturition 
pathway between the sacral spinal cord and the brain. Following suprasacral spinal cord 
injury, bladder wall C-fiber afferents, which are usually functionally silent in spinal-intact 
animals, can become activated or over-sensitized and trigger spontaneous detrusor 
contractions during bladder filling155,159,161,162.  
Our recent unpublished study suggest that a large proportion of chronically paralyzed 
pet dogs, secondary to severe, traumatic thoracolumbar spinal cord injury, exhibit C-fiber-
mediated detrusor contraction during bladder filling, or ‘detrusor overactivity’, that can lead 
to urinary incontinence. Further, along with other pathologic spinal cord reflexes such as 
involuntary pelvic limb stepping, ‘reflex voiding’ or involuntary voiding that can be elicited 
by segmental afferent stimulation of the perineum, perigenital area, tail and pelvic limbs, is 
also common in severe or chronic thoracolumbar spinal-injured dogs.  
Ironically, these animals often require regular manual bladder expression to prevent 
urine retention and potential bladder rupture as they are not able to initiate urination, which 
requires simultaneous detrusor contraction and sphincter relaxation mediated by supraspinal 
centers. In spinal-injured humans and dogs, pathologic spinal cord micturition reflex, 
mediated by hypersensitive C-fibers, can trigger concurrent detrusor and sphincter 
contractions, or ‘detrusor-sphincter dyssynergia’, that can lead to inefficient emptying, high 
residual volume, bladder over-distension and detrusor hypertrophy from chronic, persistent 
intravesical pressure elevation157 – 159,162,163.  
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C-fiber mediated detrusor-sphincter dyssynergia during voiding and detrusor 
overactivity during filling can be diagnosed using cystometry, an urodynamic test that 
assesses urinary bladder function. Although currently underutilized in veterinary medicine, 
cystometry is commonly indicated for diagnostic and monitoring purposes in people with 
urinary incontinence, including that caused by neurogenic lower urinary tract dysfunction 
such as traumatic spinal cord injury163 – 165.  In both species, cystometric outcome measures, 
such as bladder compliance, intravesical pressure and bladder storage capacity, can be 
obtained for detecting common abnormalities such as detrusor overactivity; when combined 
with sphincter electromyogram, detrusor-sphincter dyssynergia can also be diagnosed163 – 165. 
Bladder compliance is a measure of the bladder wall’s response to stretching during 
filling and it is defined as the amount of change in intravesical pressure associated with a 
specific change in intravesical volume or ΔV/ΔPa. Although 12.5 – 30 mL/cmH2O has been 
used as the lower end of normal in humans, bladder compliance can vary greatly amongst 
both spinal-intact and spinal-injured individuals163 – 167. While the generally accepted safe 
intravesical pressure threshold is in the vicinity of 40 – 50 cmH2O for humans, the 
physiologic bladder storage capacity is yet to be determined, although the range of 300 – 600 
mL/patient has been used in many human studies and 18 mL/kg has been reported in dogs162 – 
167.  
In spinal cord injury translational research, cystometric outcome measures can be 
utilized to assess the treatment effect of potential interventions in pre-human clinical models 
such as spinal-injured pet dogs. In this study, we used bladder compliance as the outcome 
measure for assessing the therapeutic effect of chondroitinase ABC on autonomic or lower 
urinary tract function. Pre-intervention cystometry data were collected on Day 0 from 
Intervention and Control groups, followed by three rechecks at Months 1, 3 and 6. We 
hypothesized that Intervention would have significantly higher compliance than Control.  
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Materials and Methods 
 
 
Study approval, written consent, patient selection and chondroitintase ABC 
administration are outlined in Chapter 2. Cystometry was performed on a conventional 
urodynamic unitoo by a blinded investigatorpp on fully conscious dogs with minimal manual 
restraint (Figure 5.2(a)). A urinary catheterqq was aseptically placed in the urinary bladder 
and 0.9% sterile saline solution was infused via a rate-adjustable pump at 10 mL/min for 
dogs < 10 Kg or 20 mL/min for dogs 10 – 20 Kg.  
 
(a)  (b) 
Figure 5.2 Cystometry Recording. (a) Recording with minimal manual restraint; (b) real-time 
recording of intravesical pressure (red) and total volume infused (blue). 
 
Total volume infused and intravesical pressure were recorded in real-time (Figure 
5.2(b)) and infusion was stopped when: (1) leaking was apparent at the external urethral 
orifice; or (2) physiologic bladder capacity of 20 mL/Kg was reached; or (3) intravesical 
pressure threshold of 50 cmH2O was reached. Compliance was determined using the formula 
ΔV/ΔPa, or change in bladder volume per unit change in intravesical pressure in mL/cmH2O.  
                                                
oo Mercury Urodynamic Module with in-built UROLAB software, Life-Tech Inc. Stafford, 
TX, USA 
pp Hilary Hu BSc BVSc 
qq Dual lumen 6.0 and 7.0 French urinary catheter, Life-Tech Inc. Stafford, TX, USA 
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Two standard points of intravesical pressure and volume were used for calculation of 
compliance: (1) at the start of infusion when both were zero; and (2) when infusion was 
stopped immediately before the start of any detrusor contraction that resulted in urine leakage 
at the external urethral orifice, or when the pressure or volume thresholds were reached. 
Statistical analysisrr of bladder compliance was done by using cross-sectional time series 
regression with the inclusion of injury chronicity and time (i.e. baseline at Day 0, Month 1, 3 
and 6) as covariates to allow for potential differences between the two groups at the 
beginning of the study.  
 
 
Results 
 
Sixty dogs were recruited but cystometry data were not available from all at all time-
points due to patient dropout, missed rechecks, and inability to place urinary catheter (Table 
5.1). Pre-intervention baseline data were available from 57/60 between Intervention and 
Control; at Month 1, data were available from 55/60; at Month 3 and Month 6, data were 
available from 52/60. General summary data comparing Intervention and Control are 
reported in Chapter 2.  
Table 5.1 Data Availability for Cystometric Evaluation. 
Time/Group Intervention Control 
Baseline 28 29 
Recheck 1 27 28 
Recheck 2 25 27 
Recheck 3 27 24 
                                                
rr Statistical analysis was performed by Dr. Nick Jeffery using Stata 11 Data Analysis & 
Statistical Software, StataCorp LP, College Station, TX. 
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Bladder compliance was measured at all four time-points and compared between 
Intervention and Control, resulting in eight groups (Table 5.2, Figure 5.3). Shapiro-Wilk Wss 
test showed that none of the eight groups was normally distributed. While compliance was 
highly variable amongst the cohort ranging from 0.4 to 339 ml/cmH2O, the medians were 
within a narrow range of 3.2 – 6.7 ml/cmH2O. 
Table 5.2 Summary of Bladder Compliance (ml/cmH2O). 
Group Q25 Median Q75 
Control Baseline 2.0 4.3 16.0 
Control Recheck 1 2.0 4.2 10.2 
Control Recheck 2 1.9 3.2 6.0 
Control Recheck 3 1.7 3.9 9.0 
Intervention Baseline 2.8 4.8 11.4 
Intervention Recheck 1 2.0 6.7 43.3 
Intervention Recheck 2 2.1 4.1 13.2 
Intervention Recheck 3 2.6 4.7 13.3 
 
 
Figure 5.3 Comparison of Bladder Compliance.  
Control = Groups 1, 3, 5 and 7; Intervention = Groups 2, 4, 6 and 8. 
                                                
ss JMP 11.0.0 (64-bit), 2013, SAS Institute Inc. 
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Following log transformation to mitigate the highly skewed data distribution, 
statistical analysis showed that neither group (Intervention versus Control) nor injury 
chronicity had a significant effect on compliance (Table 5.3). Baseline appeared to have a 
significant effect on bladder compliance, meaning that the dog’s bladder compliance at the 
beginning of the study significantly affected its value at subsequent rechecks. A mild study 
group effect may be present as P = 0.095; if it were, it would largely be explained by the 
unusually high or improved median compliance in Intervention Recheck 1 group, which was 
6.7 ml/cmH2O, while medians of the other seven groups ranged between 3.2 and 4.8 
ml/cmH2O (Table 5.2). 
 
Table 5.3 Statistical Summary of Log-transformed Chronicity-adjusted Compliance. 
Parameter  Coef Std Err z P>[z] 95% CI 
Study Group 0.46 0.28 1.67 0.10 -0.08 – 1.00 
Injury chronicity  0.01 0.01 1.13 0.26 -0.01 – 0.02 
Baseline   0.44 0.10 4.25 0.00 0.24 – 0.65 
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Intravesical pressure (Pves) and bladder storage volume at urine leaking were 
measured for calculating compliance (i.e. compliance = ΔV/ΔPa). Shapiro-Wilk Wtt test 
showed that Pves data were not normally distributed in 3/8 groups: Control Baseline, 
Intervention Baseline and Intervention Recheck 1. The results were highly variable amongst 
all groups and their medians were 15.0 – 25.0 cmH2O; the range for the cohort was 1 – 50 
cmH2O (Table 5.4, Figure 5.4). 
 
Table 5.4 Summary of Intravesical Pressure (cmH2O). 
Group Q25 Median Q75 
Control Baseline 7.0 18.0 28.5 
Control Recheck 1 10.3 19.0 31.0 
Control Recheck 2 12.0 21.0 28.0 
Control Recheck 3 14.0 23.5 30.8 
Intervention Baseline 13.3 17.0 29.5 
Intervention Recheck 1 7.0 15.0 26.0 
Intervention Recheck 2 11.5 19.0 34.5 
Intervention Recheck 3 10.0 25.0 34.0 
 
 
 
Figure 5.4 Comparison of Intravesical Pressure.  
Control = Groups 1, 3, 5 and 7; Intervention = Groups 2, 4, 6 and 8. 
                                                
tt JMP 11.0.0 (64-bit), 2013, SAS Institute Inc. 
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Storage capacity expressed as a percentage of the physiologic bladder capacity was 
compared across the eight groups. Shapiro-Wilk Wuu test determined that all groups but 
Control Baseline, Recheck 1 and Recheck 2 were not normally distributed (Table 5.5, Figure 
5.5). The group medians ranged from 46.3% to 71.3% and the storage capacity for the cohort 
ranged from 8.8% to 100%.  
Table 5.5 Summary of Bladder Storage Capacity (%). 
Group Q25 Median Q75 
Control Baseline 39.0 62.3 87.2 
Control Recheck 1 40.8 65.1 93.5 
Control Recheck 2 30.9 46.3 82.5 
Control Recheck 3 24.1 55.5 80.9 
Intervention Baseline 45.9 71.3 100.0 
Intervention Recheck 1 31.2 63.3 100.0 
Intervention Recheck 2 22.3 56.4 83.5 
Intervention Recheck 3 38.2 61.6 92.7 
 
 
 
Figure 5.5 Comparison of Bladder Storage Capacity.  
Control = Groups 1, 3, 5 and 7; Intervention = Groups 2, 4, 6 and 8. 
 
                                                
uu JMP 11.0.0 (64-bit), 2013, SAS Institute Inc. 
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Discussion 
 
Urinary bladder compliance, the predefined outcome measure for autonomic function 
in this study, was unaffected by the administration of chondroitinase ABC and remained 
largely unchanged during the six month study participation period for the cohort. Similar to 
compliance, the two explanatory variables from which compliance was directly or indirectly 
derived, intravesical pressure and bladder storage capacity, were highly variable within the 
60-dog cohort.  
While compliance ranged from 0.4 to 339 ml/cmH2O, the medians for all groups 
encompassing both experimental groups and all four time-points were within a narrow range 
between 3.2 and 6.7 ml/cmH2O, which was consistent with our recent unpublished study on 
84 severely thoracolumbar spinal-injured pet dogs. While data on normal bladder compliance 
in dogs is currently unavailable, in humans the range of 12.5 – 30 mL/cmH2O has been used 
as the lower end of normal, with high variability amongst both spinal-intact and spinal-
injured individuals163 – 167. 
Our data thus suggest that spinal-injured dogs tend to have reduced bladder 
compliance, likely caused by C-fiber-mediated detrusor contraction during bladder filling, or 
‘detrusor overactivity’, that can lead decreased bladder storage capacity and increased 
intravesical pressure, the latter could at least in part be the result of detrusor-sphincter 
dyssynergia as the bladder is triggered to contract against closed sphincters during the 
bladder filling stage155,159,161,163.  
Indeed, when compared with conscious humans (since veterinary studies are currently 
unavailable) that have a intravesical pressure threshold of 12 – 32 cmH2O before urination is 
triggered155,160,161, the Q75 of all of our eight groups (Intervention and Control at the four 
time-points) were around 30 cmH2O, or 26.0 – 34.5 cmH2O, suggesting that ~ 25% of the 60-
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dog cohort had intravesical pressure that exceeded what would be considered normal for 
humans. Further, during cytometry recording, the saline infusion was manually stopped in a 
small subset of animals in all eight groups because the intravesical pressure had reached 50 
cmH2O, or the established upper safety limit for intravesical pressure in humans and dogs162 – 
167. 
Further, bladder storage capacity was consistently lower, with group means ranging 
between 46.3% and 71.3% of the expected storage capacity based on body weight in this 
cohort, further contributing to the overall reduced bladder compliance. One likely explanation 
would be the spontaneous detrusor contractions during bladder filling resulting in urine 
leakage or incontinence. Another possible explanation would be the presence of concurrent 
urinary tract infection, which spinal-injured humans and dogs are at high risks for 
developing, resulting in pollakiuria during the participant’s clinical trial visits when 
cystometric evaluation was performed. 
Thus, the overall reduced bladder compliance, or a decreased capacity to 
accommodate volume expansion, in this 60-dog cohort in both Intervention and Control at all 
four time-points could be explained by the pathologic increase in intravesical pressure and 
decrease in bladder storage capacity as compliance measures the bladder’s response or 
resistance to volume expansion during filling, which is mathematically expressed as ΔV/ΔPa. 
Further, in a small subset of animals, the bladder compliance could have been artificially 
elevated as the result of unresponsive, ‘over-stretched’ bladders (e.g. due to infrequent 
manual bladder expression) such that the intravesical pressure would remain low despite 
significant bladder expansion.  
Additionally, the highly scattered distribution of data-points at all time-points in both 
Intervention and Control, characterized by large ranges and large inter-quartile ranges, might 
have rendered the detection of potential treatment effect more challenging due to the higher 
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probability of random errors. Although not statistically significant, study group (Intervention 
vs. Control) did appear to have a mild effect on compliance as P = 0.095, which may be more 
detectable in a larger and/or more homogenous population.  
Our ability to detect chondroitinase ABC’s therapeutic effect, if any, in future 
investigations may hence be enhanced by selecting a more homogenous group of subjects 
based on, for instance, similar spinal cord injury severity, comparable injury chronicity or 
baseline compliance that falls within a narrower range. Alternatively, larger sample sizes 
could be used in future studies to identify potential subgroup(s) that may be more responsive 
to the therapeutic effect of chondroitinase ABC.  
Further, Intervention Recheck 1 at one month post-injection had an unusually high or 
improved median compliance compared to Control, but returned to baseline level at Recheck 
2 and remained low at Recheck 3. The current chondroitinase ABC formulation has a 
reported in vivo efficacy for up to six weeks75. Our finding suggests that improvement in 
bladder compliance could possibly be sustained or even enhanced by repeat dosing after one 
month, or by extending the therapeutic life of a single delivery beyond one to three months 
by, for instance, using gene therapy and a lentiviral vector to transduce the host cells to 
express chondroitinase ABC76.  
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CHAPTER 6 
CLINICAL EVALUATIONS 
 
 
 
Introduction 
 
 
Objective outcome measures, as presented in Chapters 3 – 5, were used in the current 
60-dog Phase II clinical trial for detecting change in neurologic function over six months 
primarily because of their higher degrees of reproducibility. Since Phase II trials are usually 
preliminary efficacy studies for detecting therapeutic and adverse effects of a novel 
intervention, less readily quantifiable clinical outcome measures can help further our 
understanding of chondroitinase ABC by providing detailed, individualized and clinically 
relevant data regarding its efficacy and safety.  
Clinical evaluation made by the investigator and pet owners can be highly valuable in 
translational spinal cord injury research. Firstly, the neurologic function of a spinal-injured 
pet dog, such as ambulation, can vary substantially from day to day even in the chronic 
phasevv of injury. Owners’ observations of functional changes at home would thus 
supplement in-hospital evaluations at a given time. 
Secondly, some study-associated complications, such as urinary tract infections 
secondary to urinary catheterization for cystometric evaluation, may not be apparent during 
hospitalization. Thus, investigator would need to rely on the owners’ observations for 
estimating the true incidences of study-related events in the cohort. 
Moreover, certain clinical parameters are highly relevant for spinal-injured pet dogs 
because: (1) some, such as deep pain, are widely accepted standards for assessing and 
                                                
vv Chronic phase typically begins ~ 3 months post-injury when the dog’s neurologic status 
plateaus. Spontaneous neurologic recovery is unlikely to occur at this point.  
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communicating the degree of neurologic impairment and treatment-related recovery amongst 
clinicians and investigators; (2) some, such as urinary continence, are functional parameters 
that owners highly value and (3) failure to regain these functions can lead to clinically-
significant decisions such as euthanasia.  
Additionally, potential adverse drug effects that are specific to intrathecal 
chondroitinase ABC administration, such as injection-site neuropathic pain as evidenced by 
hyperalgesia and allodynia that might occur secondary to glial scar digestion and 
neuroplasticity-induced aberrant axonal sprouting, can be detected by simple means including 
clinical examination and von Frey sensory testing. 
We herein present the clinical evaluations made by the investigator and owners 
regarding the potential therapeutic and adverse effects of chondroitinase ABC, as well as the 
study-related complications. Subjectivity of these outcome measures were mitigated by 
providing clear definitions of specific outcomes, with the goal of enhancing inter-observer 
agreeability and experimental reproducibility. 
 
 
 
Materials and Methods 
 
 
Study approval, written consent, patient selection and chondroitintase ABC 
administration are outlined in Chapter 2. Assessments performed at pre-intervention Day 0 
and Months 1, 3 and 6 included: (1) von Frey filament sensory testing as a mechanical 
nociceptive threshold test to detect abnormal sensation; (2) owner questioning regarding 
potential treatment effect, adverse reaction and study-related complications; (3) presence of 
deep pain in pelvic limbs; and (4) ability to ambulate. 
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Von Frey sensory test was performed on fully conscious dogs with minimal manual 
restraint in a familiar, quiet room with little distraction by a blinded investigatorww. The test 
was performed the day before injection to obtain a baseline, the morning after injection, and 
at three rechecks. Each of the 17 filaments was applied one at a time perpendicular to the 
dog’s dorsum, one side at a time ~ 2 cm lateral to the dorsal midline, until the filament 
slightly deformed.  
The filaments were applied starting from the level of L5 – L6 dorsal spinous 
processes and were moved cranially one vertebra at a time up to the level of T6 – T7, which 
was > 2 vertebrae cranial to the site of injury or injection. A response was considered 
‘abnormal’ if the dog showed any reaction suggestive of discomfort or pain, including 
vocalization, exaggerated movement or aggression in response to the stimulus. A response 
was considered ‘present’ if the dog turned around to look or exhibited panniculus reflexxx. 
The number of positive response on both sides were added to obtain the total for each animal.   
Owner questioning was done during their pet’s clinical trial participation and after 
completion. At Month 1, 3 and 6 rechecks, each blinded owner was asked by the blinded 
investigator ‘Have you noticed any problems since the last visit?’ and ‘Have you noticed any 
changes since the last visit?’. At the last visit after all relevant data had been collected, the 
blinded owner was asked ‘Do you think your pet received the injection six months ago?’; 
statistical analysisyy was done by first scoring if the owners had correctly guessed the group 
assignment, then comparing the score with random probability, or guessing correctly 50% of 
the time, using Fisher’s exact test. 
Post-study follow-up for the first 42 participants was done six months after their last 
visits via email with owners and, due to thesis deadline, up to five months after their last 
                                                
ww Hilary Hu BSc BVSc 
xx Panniculus reflex is observed as a brief paraspinal skin twitch mediated by cutaneous 
trunci muscles in response to a sensory stimulus. 
yy Stata 11 Data Analysis & Statistical Software, StataCorp LP, College Station, TX. 
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visits for the last 18 participants. Each owner was asked ‘Have you noticed any problems 
since completion of the clinical trial?’ and ‘Have you noticed any changes since completion 
of the clinical trial?’.  
Pelvic limb deep pain perception was tested on fully conscious dogs with minimal 
manual restraint in a familiar, quiet room with minimal distraction by firmly crushing the nail 
bed and digit with forceps in dogs < 10 kg or pliers in dogs 10 – 20 kg87 – 89. Deep pain was 
considered ‘present’ if the dog repeatedly vocalized and/or turned his/her head towards or 
attempted to bite the source of stimulus.  
Ambulation was assessed by observing the dog’s ability to walk on non-slippery 
surfaces such as grass or carpet. A dog was considered ‘ambulatory’ if he/she was able to 
walk ten consecutive steps unaided without falling or the lateral aspect of the foot or 
metatarsus touching the ground. 
 
 
Results 
 
Sixty dogs were recruited but results were not available from all at all time-points due 
to patient dropout and missed rechecks (Table 6.1). Pre-intervention baseline data were 
collected at Day 0 from 60/60 between Intervention and Control; at Month 1, data were 
available from 58/60; at Month 3, from 55/60; and at Month 6, from 52/60. General summary 
of Intervention and Control are reported in Chapter 2. 
Table 6.1 Data Availability for Clinical Evaluation. 
Time/Group Intervention Control 
Baseline 30 30 
Recheck 1 29 29 
Recheck 2 27 28 
Recheck 3 27 25 
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No abnormal response suggestive of neuropathic pain was detected with Von Frey in 
the cohort. The total number of response was the highest in both Control and Intervention 
shortly (12 – 24 hours) following injection, but decreased to sub-baseline levels by Recheck 1 
and remained low until study completion (Table 6.2, Figure 6.1). Shapiro-Wilk Wzz test 
showed that none of the groups was normally distributed. Total response were 0 – 32 for the 
cohort; while medians for all groups were 0. 
Table 6.2 Von Frey Sensory Test Summary. 
Groupsaaa Q25 Median Q75 
Control B1 0 0 3 
Control B2 0 0 6 
Control R1 0 0 2 
Control R2 0 0 3 
Control R3 0 0 6 
Intervention B1 0 0 4 
Intervention B2 0 0 8 
Intervention R1 0 0 1 
Intervention R2 0 0 1 
Intervention R3 0 0 0 
 
 
Figure 6.1 Comparison of Number of Von Frey Response. 
Control = Groups 1, 3, 5, 7 and 9; Intervention = Groups 2, 4, 6, 8 and 10. 
                                                
zz JMP 11.0.0 (64-bit), 2013, SAS Institute Inc. 
aaa B1 = baseline before injection; B2 = baseline after injection; R = recheck. 
83 
 
 
Ambulation was evaluated at rechecks and compared with Baseline, where 4/30 of 
Control and 5/30 Intervention were ambulatory (Figure 6.2). At Recheck 1, 4/30 Control and 
8/29 Intervention were ambulatory. By Recheck 2, 4/28 Control and 8/27 Intervention were 
ambulatory. At Recheck 3, the numbers were 4/25 and 8/27 for Control and Intervention, 
respectively. In total, three participants regained ambulation during the study, all from 
Intervention. 
 
Figure 6.2 Proportion of Ambulatory Participants. 
 
Deep pain perception was evaluated at each recheck and compared with the baseline, 
where 2/30 of Control and 4/30 Intervention had deep pain (Figure 6.3). At Recheck 1, 5/30 
Control and 4/29 Intervention participants were deep pain-positive. By Recheck 2, 5/28 
Control and 4/27 Intervention were deep-pain positive. At Recheck 3, the numbers were 6/25 
and 5/27 for Control and Intervention. In total, six participants regained deep pain during the 
study, of which, four were from Control. 
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Figure 6.3 Proportion of Participants with Deep Pain Sensation. 
 
Owners were questioned regarding observable changes and/or problems since the 
previous visit (Figure 6.4). For Intervention, owners reported changes in 19/29, 12/27 and 
12/27 participants at Rechecks 1, 2 and 3, respectively. Similarly, 21/29, 15/28 and 10/25 
owners whose pets had been randomized to Control reported positive findings at the three 
rechecks. Main changes reported included: increased pelvic limb movement when on the 
floor and/or in their carts, improved ability to ambulate and stand and remain standing on 
their pelvic limbs, increased tail movement and more responsive to touch in the caudal half of 
the body including the pelvic limbs.  
 
Figure 6.4 Owner Questioning Regarding Changes. 
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Owners were also asked about their observation of any problems associated with or 
since the previous visit (Figure 6.5). For Intervention, owners reported problems in 8/30, 
3/29, 2/27 and 0/27 of the participants at Baseline and Rechecks 1, 2 and 3, respectively; 
while 1/30, 2/29, 5/28 and 3/25 owners whose pets had been randomized to Control reported 
problems at these four time-points. Problems mainly included diarrhea, urinary tract 
infection, reduced mobility for 1 – 3 days, skin ulceration and sensitivity to back palpation.  
 
Figure 6.5 Owner Questioning Regarding Problems. 
 
Forty-two of the 60 owners were asked at the end of the study following data 
collection but before unblinding to speculate which experimental group their dog had been 
assigned six months prior. For Control, 6/22 owners believed that their pets had been 
assigned to Intervention, while 11/20 of Intervention owners did (Figure 6.6). Owners 
correctly guessed group assignment in 27/42 or 64.3% of the cases and were incorrect in 
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15/42 or 35.7%; statistical analysisbbb using Fisher’s exact test showed that, with P = 0.34, 
this was not significantly better than random probability of 50%. 
 
Figure 6.6 Owner Speculation of Group Assignment. 
 
Lastly, of the 52 participants that had completed the study, post-study follow-up data 
were available from 48, 24 from either group. None of the owners observed any problems 
since study completion and 10/24 or 42% owners of Intervention reported continued changes, 
which mainly included increased attempts and duration of weight-bearing and ambulation on 
their pelvic limbs and improved urinary continence; while 14/24 or 56% owners of Control 
that received chondroitinase ABC after study completion reported changes, which included 
increased attempts and duration of weight-bearing and ambulation on pelvic limbs. 
 
 
 
                                                
bbb Statistical analysis was performed by Dr. Nick Jeffery using Stata 11 Data Analysis & 
Statistical Software, StataCorp LP, College Station, TX. 
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Discussion 
 
Clinical evaluation made by the investigator and owners suggested that while 
chondroitinase ABC had no clinically detectable adverse effects, it might have some 
detectable therapeutic effect in a subgroup of study subjects. As evidenced, neither 
observational evaluation nor von Frey sensory test identified evidence indicative of pain or 
discomfort associated with intrathecal chondroitinase ABC administration. 
However, despite the lack of evidence for neuropathic pain, positive von Frey 
response peaked in Control and Intervention 12 – 24 hours post-injection, but declined to 
sub-baseline levels by Month 1 and remained low. One possible explanation for this surge of 
positive von Frey response, which coincided with an increased number of owner-reported 
problems following chondroitinase ABC injection at Day 0, would be that the intrathecal 
drug delivery could have caused some minor damage to the soft tissues at/near the injection 
sites.  
Another potential cause of increased sensitivity to mechanical stimulation delivered 
by the von Frey filaments would be the surgical preparation protocol for the intrathecal 
injection, which involved processes that might have irritated the skin, such as hair clipping 
and surgical scrubbing.  
Evidence supportive of the detectable therapeutic effect of chondroitinase ABC, on 
the other hand, was equivocal as while the owners were unable to correctly surmise which 
experimental group their pet had been assigned six months prior, twice as many Intervention 
owners thought their pet had received the injection compared with Control. Further, three 
dogs in Intervention regained ambulation during the six-month participation period, while 
none of the Control did.  
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Statistical analysis was not performed in this case because of the small number of 
participants that qualified as ‘ambulatory’. However, upon closer examination of these three 
dogs (Dogs 23, 28 and 34) that regained ambulation during the study, it appears that they 
possessed overall superior neurologic function than the rest of the cohort at the time of study 
enrolment.  
Dogs 28 and 34 had only been paralyzed for four to five months at the time of 
enrolment and had intact deep pain and some motor function in their pelvic limbs, implying 
functionally incomplete or partially recovered spinal cord injuries. Dog 23, albeit remained 
deep pain negative during the study and had been non-ambulatory for 24 months at the time 
of enrolment, had remarkable pelvic limb stepping reflexes and was already able to weight-
bear and walk several steps on her pelvic limbs.  
Therefore, it is possible that chondroitinase ABC may benefit a certain subgroup, 
namely, individuals that have incomplete or partially recovered spinal cord injuries and/or a 
certain degree of pelvic limb motor function, either mediated by supra-spinal input (i.e. Dogs 
28 and 34 that had intact deep pain) or segmental spinal cord reflex (i.e. Dog 23 that was 
deep pain negative but had strong reflex stepping).   
Further, all three dogs were small breed that weighted 4.2 – 6.0 kg; their small body 
size could have made it easier for them to support most of their body weight with their 
thoracic limbs and thus rendered them more likely to ambulate and receive afferent 
stimulation via their pelvic limbs to facilitate reflex-mediated stepping through mechanisms 
similar to those reported in experimental dogs and cats that are deprived of normal 
supraspinal locomotor control, but can be trained and/or stimulated to repetitively step and 
ambulate 111 – 113,119 – 125. 
Additionally, all three Intervention dogs regained ambulation one month post-
injection, which coincided with the temporary improvement in bladder compliance. Thus, it 
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can be deduced that the possible therapeutic effect would occur Day 0 – Month 1, and 
improvement in neurologic function could be sustained or even enhanced by repeat dosing 
after one month, or by extending the therapeutic life of a single delivery beyond one to three 
months by, for instance, using gene therapy and a lentiviral vector to transduce the host cells 
to express chondroitinase ABC76. 
Interestingly, while three Intervention participants regained ambulation during the 
six-month study participation period, two Intervention and four Control participants regained 
deep pain perception over the same period. Since all participants were enrolled > 3 months 
post-injury, or during the chronic injury phase when spontaneous neurologic recovery is 
unlikely to occur, our results suggest that continued neurologic recovery is possible beyond 
the first three months of injury in a subset of patients, with or without chondroitinase ABC.  
One possible explanation for the clinical improvement during the chronic phase 
would be the benefit of rehabilitation therapy, which the study participants underwent during 
each of their weeklong hospital visit. In experimentally spinal-injured rats, specific 
rehabilitation regimens, either administered alone or in conjunction with chondroitinase 
ABC, can improve motor outcomes68. While its benefit in chronically spinal-injured dogs is 
unknown, rehabilitation therapy can provide sensory stimulation that promotes segmental 
central pattern generator-mediated reflexes that trigger stepping and ambulation111 – 114,119 – 
125.  
Lastly, while statistical analysis indicated that the accuracy of owners’ guesses were 
no better than random probability, twice as many Intervention owners speculated that their 
pets had received the chondroitinase ABC than Control owners, or 55% versus 27%. The 
relatively small sample size of 48 could partially account for the lack of detection of 
statistical significance. It is also possible that there was a small, more treatment-responsive 
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subgroup in Intervention, in which case a larger study may be warranted to detect 
chondroitinase ABC’s treatment effect, if any, in a subpopulation.   
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CHAPTER 7 
CONCLUSIONS 
 
 
The current Phase II double-blinded randomized controlled chondroitinase ABC 
clinical trial in 60 severely thoracolumbar spinal-injured pet dogs failed to demonstrate a 
statistically significant group treatment effect, pre-defined as 25% dogs in Intervention and 
0% dogs in Control recovering thoracic-pelvic limb gait coordination measured by phase 
shift by Month 6. Secondary parameters, including motor-evoked and sensory-evoked 
potentials and bladder compliance, also detected no significant treatment effect of this 
putative drug for spinal cord injury. 
The lack of detectable therapeutic effect of chondroitinase ABC in the current study 
could be multi-factorial. Firstly, since this was the first study in a large animal model, the 
dose of chondroitinase ABC had been unknown; therefore, it is possible that the dose 
administered was sub-therapeutic. The lack of report of potential side effects and adverse 
reactions in Intervention would indirectly support this speculation.  
Secondly, intrathecal chondroitinase ABC administration was very challenging at 
times, especially in the study participants that had, presumably, injury- or surgery-induced 
soft tissue fibrosis and osseous proliferation at and/or near the injection sites, hindering the 
precision of spinal needle placement for full-dose drug delivery despite the use to 
fluoroscopy-guided spinal needle placement technique.  
Due to the clinical nature of these cases, one significant limitation of this study was 
that labelling and tracing could not be practically implemented to confirm successful drug 
delivery; for instance, was the full dose actually administered into the spinal cord 
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parenchyma or was it only injected into the cystic cavity or syrinx, which would probably 
just ‘leak out’ as soon as the spinal needle was withdrawn?  
Further, albeit we used a thermo-stabilized, slow-release formulation of 
chondroitinase ABC that is shown in vivo to sustain its chondroitin sulfate proteoglycan-
suppressive effect for up to 6 weeks post-treatment75, the duration of drug effect in the 
current large animal model could not easily be confirmed by means such as in vivo labelling 
and harvesting spinal cord samples for examination.  
On the other hand, clinical evaluations, that were focused on detecting clinically 
observable treatment effect and adverse effects, suggested that chondroitinase ABC is a very 
safe agent when delivered intrathecally with fluoroscopy guidance at the current dose. 
Conversely, one could argue that the dose used in the current study might have been sub-
therapeutic, thus, at least in part, account for the lack of detectable treatment effect.  
In addition to dose adjustment, challenges associated with the current method of drug 
administration should be addressed in future investigations to ensure more accurate delivery 
of the drug at its intended dose. One alternative would be to administer chondroitinase ABC 
during the acute phase of spinal cord injury, such as intra-operatively. Immediate drug 
delivery may also be more efficacious as most experimental animal models that report 
measurable therapeutic effect involve drug delivery during the acute phase of spinal cord 
injury. 
While the power calculation was intended to detect a treatment effect of 25% 
improvement in thoracic-pelvic limb phase shift, it is possible that a smaller treatment effect 
could exist but would require a larger sample size for its statistical detection. A larger sample 
size may also assist with the identification of potential subgroups differentiated by clinical 
parameters such as injury severity and chronicity, which may be more responsive to the 
treatment effect of chondroitinase ABC.  
93 
 
Indeed, there was some evidence in the current study that would support the possible 
existence of more treatment-responsive subgroups as three Intervention dogs regained 
ambulation during the study participation period; all three possessed superior levels of motor 
function, suggestive of functionally incomplete or partially recovered and/or recovering 
spinal cord injuries, compared to the rest of the cohort when they entered the study. 
Further, the permanent improvement in motor function temporally coincided with the 
temporary improvement in bladder compliance in Intervention one month post-treatment. It 
can thus be deduced that the possible therapeutic effect would likely occur Day 0 – Month 1, 
and that the neurologic improvement could be sustained or even enhanced by repeat dosing 
after one month, or by extending the therapeutic life of a single delivery by, for instance, 
utilizing novel means such as gene therapy76. 
In conclusion, while our study failed to detect a therapeutic effect in chronic, severe 
thoracolumbar spinal-injured dogs, it has established drug safety in a clinical large animal 
model for traumatic spinal cord injury. Thus, this study has provided a platform for future 
investigations in which the dose, route and timing of chondroitinase ABC administration, as 
well as patient selection, can be adjusted to maximize its potential therapeutic effect and 
benefit spinal-injured human and veterinary patients. Identification of more treatment-
responsive subgroups in future studies would assist with the development of personalized 
treatment, rendering the successful clinical translation of putative spinal cord injury 
intervention more likely.  
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APPENDIX 
 
APPENDIX A [CLINICAL TRIAL BROCHURE] 
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APPENDIX B [CHONDROITINASE ABC DOSING CALCULATIONS] 
 
 
 
Prepping Microtubes 
 
 
General Concept:   
 
Dry microtubes can be loaded simply by resuspending in the chABC solution. The loaded 
concentration is equivalent to the concentration of the chABC solution with a loading volume 
of 7.5ul per 10mg of lipid (1 tube). After this, delivery of drug is thought to be entirely 
diffusion limited. It is possible to remove unloaded solution (centrifugation) or simply inject 
with loaded and unloaded drug (equivalent to including a bolus injection of free drug at the 
same time as delivering microtubes).  This is beneficial when the injury is not new, and there 
may already be a build up for a scar (the current experiment).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
 
Protocol Design Considerations:  
 
• We want to initially resuspend in a high concentration of chABC solution to get 
maximal loading,  
• Minimum resuspension volume is ~40ul/mg lipid; (this leads to a large amount of 
chABC wasted) 
• Attempts to aliquot microtubes into smaller containers prior to lyophilization has (as 
of yet) proved unsuccessful so we are stuck at 10mg/tube. 
• Lipid microtubes begin releasing chABC immediately so should be prepped as closely 
as possible to the surgery date, or kept in the high concentration solution until 
immediately before injection so there is no concentration gradient to drive diffusion. 
 
Detailed Protocol: 
 
Supplies: 
• 10 mg Tube of Microtubes 
• 1 5U Bottle of chABC 
• Sterile 38% Trehalose Buffer (can be re-sterilized by syringe filter) 
 
Equipment: 
• Micropipettes + Tips 
• Sterile Laminar Flood Hood (if possible) 
• Needles/Syringes 
• Sterile Eppendorf Tubes (0.5 ml preferred) 
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Prepping ChABC: 
 
1.  Thaw chABC (preferably in a dehumidying chamber)  ~ 15 minutes prior to starting 
2.  In laminar flow hood, inject 800ul 38% Trehalose Buffer into chABC bottle using a sterile 
syringe. 
3. Mix thoroughly by shaking/swishing chABC bottle until all white power is dissolved.  
(TIP: MAKE SURE TO TURN BOTTLE UPSIDE DOWN TO DISSOLVE chABC that 
stick to the lid). 
4. Remove stopper and aliquot using sterile pipettes into 2 400ul aliquots. 
5. Store these at -80°C or -20°C until needed. 
 
 
Resuspending Microtubes   (Night before surgery --or possibly slightly before that). 
1.  Thaw 1 chABC aliquot. 
2. In hood: add 400ul of chABC stock solution to 1 tube of 10mg lipid microtubes. 
3. Mix tubes by gentle pipetting up and down with a P1000 micropipettes (TIP: Best done if 
the very tip of the pipette is cut off so the hole is bigger) 
4. Store overnight at 4°C 
 
 
Aliquot Microtubes  (aliquots at the high concentration will minimize loss of loaded drug). 
1. In laminar hood, aliquot 4 X 100 ul of the microtubes/chABC solution. 
2. These can be stored for a maximum of 2 weeks at 4°C for each dog. 
 
 
Day of Surgery:  (2 options) 
 
High Initial Release (Bolus Injection) 
1. Inject the 100ul as desired using the smallest gauge needle possible (18 or 20; 
largest internal diameter to minimize breaking the tubes). 
 1b. can also increase the volume/reduce viscosity if desired using additional 
sterile trehalose solution 
Total chABC Delivered 625 mU 
Total Loaded chABC ~12 mU 
Total Free chABC ~613 mU 
This can be altered by further dilution because will reduce viscosity. 
 
Lower Initial Release 
1. In hood, add extra trehalose buffer (300ul). 
2. Centrifuge at 1500rpm for 10 min. 
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3. In hood, remove supernatant and add sterile trehalose solution up desired injection 
volume. (exact amount of free chABC will depend on how effectively the supernatant 
can be removed). 
Total chABC Delivered** 12mU 
Total Loaded chABC 12mU 
Total Free chABC 0mU 
** assuming 100% removal of supernatant which is not physically reasonable 
 
Total chABC Delivered** 165mU 
Loaded chABC ~12mU 
Free chABC ~153mU 
** assuming 75% removal of supernatant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
